Risk Factors Regarding Zoonotic Patients with Chronic Prostatitis

Acetaminophen for the Management of Zoonotic Disease among Community

Diseases
Cancer, Ophthalmology & Pediatric

VOLUME 19 ISSUE 4 VERSION 1.0

Online ISSN: 2249-4618
Print ISSN: 0975-5888
DOI: 10.17406/GJMRA

Global Journal of Medical Research: F

Discovering Thoughts, Inventing Future
**EDITORIAL BOARD**

**GLOBAL JOURNAL OF MEDICAL RESEARCH**

<table>
<thead>
<tr>
<th><strong>Dr. Jixin Zhong</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Department of Medicine, Affiliated Hospital of Guangdong Medical College, Zhanjiang, China, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH 43210, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Han-Xiang Deng</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>MD., Ph.D. Associate Professor and Research Department Division of Neuromuscular, Medicine Davee Department of Neurology and Clinical Neurosciences Northwestern, University Feinberg School of Medicine, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Rama Rao Ganga</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>MBBS MS (University of Health Sciences, Vijayawada, India) MRCS (Royal College of Surgeons of Edinburgh, UK) United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Roberto Sanchez</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Associate Professor Department of Structural and Chemical Biology Mount Sinai School of Medicine Ph.D., The Rockefeller University, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Feng Feng</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Boston University Microbiology 72 East Concord Street R702 Duke University, United States of America</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. William Chi-shing Cho</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph.D., Department of Clinical Oncology Queen Elizabeth Hospital Hong Kong</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Lisa Koodie</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph.D in Pharmacology, University of Minnesota Medical School, Minnesota, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Yash Kapadia</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Doctor of Dental Surgery, University of Louisville School of Dentistry, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Krishna M Vukoti</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph.D in Biochemistry, M.Tech in Biotechnology, B.S in Pharmacy, Case Western Reserve University, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Guodong Niu</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph.D in Entomology, M.S. in Microbiology, B.S in Environmental Science, The Pennsylvania State University, University Park, PA, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Arpita Myles</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph.D, M.Sc. in Biotechnology, B.Sc in Microbiology, Botany and Chemistry, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Xingnan Li</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph.D in Cell Biology, B.S in Molecular Biology, Stanford University, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Michael Wink</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph.D., Technical University Braunschweig, Germany Head of Department Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Wael Ibrahim Abdo Aikhiary</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph.d, M.Sc in Clinical Pathology, MBBCCH, M.D in Medicine, Mansoura University, Faculty of Medicine, Egypt</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Affiliations</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Dr. Izzet Yavuz</strong></td>
<td>Ph.D, M.Sc, D Ped Dent. Associate Professor, Pediatric Dentistry Faculty of Dentistry, University of Dicle, Turkey</td>
</tr>
<tr>
<td><strong>Dr. Sunil Sirohi</strong></td>
<td>B.Pharm in Pharmaceutical Sciences, MS in Pharmacology, B.Ph.D in Pharmacology, Washington State University, Pullman, WA, United States</td>
</tr>
<tr>
<td><strong>Dr. Rabiatul Basria SMN Mydin</strong></td>
<td>Ph.D in Cancer Genetics, BSc (HONS) in Biotechnology, University of Science Malaysia, Malaysia</td>
</tr>
<tr>
<td><strong>Dr. Tsvetelina Velikova</strong></td>
<td>Ph.D, MD in Clinical Immunology, Medical University of Sofia Sofia University, Bulgaria</td>
</tr>
<tr>
<td><strong>Dr. (Mrs.) Sunanda Sharma</strong></td>
<td>Ph.D, M.V.Sc., AH, M.V.Sc in Animal Reproduction, Veterinary Obstetrics and Gynaecology, College of Veterinary &amp; Animal Science, Rajasthan Agricultural University, Bikaner, India</td>
</tr>
<tr>
<td><strong>Dr. M. Alagar Raja</strong></td>
<td>Ph.D in Pharmaceutical Sciences, M.Pharmacy in Pharmaceutical Analysis, B.Pharmacy S. Chattanatha Karayalar College of Pharmacy, Nalanda College of Pharmacy Tenkasi, Tamil Nadu, India</td>
</tr>
<tr>
<td><strong>Dr. Subhadra Nandakumar</strong></td>
<td>Ph.D., M.Sc in Applied Microbiology, B.Sc in Microbiology, University of Madras, India</td>
</tr>
<tr>
<td><strong>Sanguansak Rerksuppaphol</strong></td>
<td>Department of Pediatrics Faculty of Medicine Srinakharinwirot University NakornNayok, Thailand</td>
</tr>
<tr>
<td><strong>Dr. Sultan Sheriff Dhaustagir</strong></td>
<td>Ph.D, M.Sc in Medical Biochemistry, Faculty of Medicine, Garyounis/Benghazi University, Libya</td>
</tr>
<tr>
<td><strong>Dr. Pejcic Ana</strong></td>
<td>Assistant Medical Faculty Department of Periodontology, and Oral Medicine University of Nis, Serbia</td>
</tr>
<tr>
<td><strong>Dr. Seung-Yup Ku</strong></td>
<td>M.D., Ph.D., Seoul National University Medical College, Seoul, Korea Department of Obstetrics and Gynecology Seoul National University Hospital, Seoul, Korea</td>
</tr>
<tr>
<td><strong>Dr. Ivandro Soares Monteiro</strong></td>
<td>M.Sc., Ph.D. in Psychology Clinic, Professor University of Minho, Portugal</td>
</tr>
<tr>
<td><strong>Dr. Pina C. Sanelli</strong></td>
<td><strong>Dr. Michael R. Rudnick</strong></td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Associate Professor of Radiology Associate Professor of Public Health Weill Cornell Medical College Associate Attending Radiologist NewYork-Presbyterian Hospital MRI, MRA, CT, and CTA Neuroradiology and Diagnostic Radiology M.D., State University of New York</td>
<td>M.D., FACP Associate Professor of Medicine Chief, Renal-Electrolyte and Hypertension Division (PMC) Penn Medicine, University of Pennsylvania Presbyterian Medical Center, Philadelphia Nephrology and Internal Medicine Certified by the American Board of Int, United States</td>
</tr>
<tr>
<td><strong>Dr. Alfio Ferlito</strong></td>
<td><strong>Dr. Rajeev Vats</strong></td>
</tr>
<tr>
<td>Professor Department of Surgical Sciences University of Udine School of Medicine, Italy</td>
<td>Ph.D., M.Sc., B.Sc in Zoology, M.Phil in Bioinformatics, PGDCA, The University of Dodoma, Tanzania</td>
</tr>
</tbody>
</table>
i. Copyright Notice
ii. Editorial Board Members
iii. Chief Author and Dean
iv. Contents of the Issue

1. Considerations Necessary Regarding Prostate Cancer with the Options of Surgical Removal of the Prostate Gland or with Androgen Deprivation (Aka Testosterone Inactivating) Therapy (ADT) as Follow-on or Primary Treatment. 1-2

2. Health Seeking Behavior, Cost of Illness and Quality of Life of Patients with COPD among 35 Years & above Rural Population of Gurugram, Haryana. 3-7

3. Ratio of Zinc to Bromine, Iron, Rubidium, and Strontium Concentration in the Prostatic Fluid of Patients with Chronic Prostatitis. 9-15

4. Assessment of Knowledge and Associated Risk Factors Regarding Zoonotic Disease among Community Members of Siddharthanagar Municipality, Bhairahawa, Rupandehi. 17-27

5. Efficacy of Intravenous Acetaminophen Compared to Oral Acetaminophen for the Management of Fever in Children. 29-40

v. Fellows
vi. Auxiliary Memberships
vii. Preferred Author Guidelines
viii. Index
Considerations Necessary Regarding Prostate Cancer with the Options of Surgical Removal of the Prostate Gland or with Androgen Deprivation (Aka Testosterone Inactivating) Therapy (ADT) as Follow-on or Primary Treatment

By Charles Maack


With surgical removal of a cancerous prostate gland, PSA nadir should drop to near total absence well into the ultrasensitive testing level below 0.5ng/ml. If this is not achieved, it is likely all cancer cell activity has not been removed, and further treatment is necessary.

A variety of tests should be performed for baseline markers among which should be free Testosterone to determine level as well as any bone issues; deoxypyridinoline (DpD) urine test to determine bone resorption; prolactin level since if high could inhibit ADT therapy as well as cause several other issues (See: https://tinyurl.com/7w5omeo); lipid or fatty acid profile since both de novo and dietary lipids seem to be important contributors to prostate cancer growth and development; inflammation markers since inflammation may drive resistance to androgen deprivation therapy (ADT); and any other markers to aid in determining the best strategy for treatment.
Considerations Necessary Regarding Prostate Cancer with the Options of Surgical Removal of the Prostate Gland or with Androgen Deprivation (Aka Testosterone Inactivating) Therapy (ADT) as Follow-on or Primary Treatment

Charles Maack

**INTRODUCTION**

Charles (Chuck) Maack (ECaP) – Prostate Cancer continuing patient since 1992, Advocate, Activist, and Mentor to Men so diagnosed and their Caregivers online Worldwide.

With surgical removal of a cancerous prostate gland, PSA nadir should drop to near total absence well into the ultrasensitive testing level below 0.5ng/ml. If this is not achieved, it is likely all cancer cell activity has not been removed, and further treatment is necessary.

A variety of tests should be performed for baseline markers among which should be free Testosterone to determine level as well as any bone issues; deoxypyridinoline (DpD) urine test to determine bone resorption; prolactin level since if high could inhibit ADT therapy as well as cause several other issues (See: https://tinyurl.com/7w5omeo); lipid or fatty acid profile since both de novo and dietary lipids seem to be important contributors to prostate cancer growth and development; inflammation markers since inflammation may drive resistance to androgen deprivation therapy (ADT); and any other markers to aid in determining the best strategy for treatment.

If imaging is unable to identify the presence of metastasis, Androgen Deprivation (aka testosterone inactivating) Therapy (ADT) should be considered, or salvage radiation in company with ADT. Continuing presence of cancer activity should be met with the intent of eradication, or at least long-term control and management. Treatment with minimal ADT medications with the idea that additional medications would be added when the earlier fail, can lead to unexpected accelerated cancer activity and if not noticed early on can contribute to early mortality. All avenues that contribute to cancer cell growth and proliferation should be addressed.

Since testosterone (aka androgen) is a known stimulator to such growth, production sources of testosterone should be inhibited. Keeping in mind “do no harm,” an antiandrogen, with bicalutamide (generic of Casodex) most often prescribed, (flutamide/Eulexin or nilutamide/Nilandron also available) should first be prescribed beginning a week prior to prevent a “flare” effect of sudden testosterone production if then adding the next necessary medication of LHRH agonists Lupron, Trelstar, Eligard, or Zoladex. If initially prescribing the antagonist degarelix/Firmagon, the antiandrogen can be prescribed simultaneously or following this medication since it does not cause the “flare” effect.

The antiandrogen serves to inhibit androgen precursors produced by the adrenal glands travelling to cancer cell androgen receptors. The foregoing are the two initial medications that should be prescribed, and then testosterone as well as prostate-specific antigen (PSA) levels closely monitored since both should significantly drop to indicate ADT effectiveness. If an agonist is prescribed, I would encourage initial administration be a single month dose until it is determined PSA and testosterone levels have significantly dropped indicating the lurking cancer cells are androgen dependent. A testosterone level of 20ng/dl or below indicates effective testosterone clinical castration/control. A PSA level dropping to a nadir of less than (<) 0.5ng/dl is expected and also indicates these medications are serving their role. If the PSA level does not drop below 0.5ng/ml, testosterone may still be reaching 5 Alpha Reductase (5AR) enzymes while enroute to cancer cell androgen receptors. When that is the case, these enzymes convert testosterone to dihydrotestosterone (DHT), a much more powerful stimulant to cancer cell growth and proliferation. To inhibit this conversion, the addition of the 5AR inhibitor (5ARI) dutasteride/Avodart should be considered. The prescribing of these three medications in combination is considered ADT3, also known as triple androgen/testosterone/hormonal blockade.

When ADT3 with the foregoing medications show failure by rising PSA, other medications manufactured to replace the antiandrogen and...
Evidence to suggest that more contemporary methods of delivering ADT may reduce cardiovascular risk.”

Dr. Matthew Roe, a Professor of Medicine at Duke University’s Clinical Research Institute (DCRI), the Faculty Director of the Global Outcomes Commercial MegaTrials program, and the Director of their Fellowship Program, remarks: “If a patient who has advanced prostate cancer and known cardiovascular disease is being considered for androgen deprivation therapy, it is important that he speak with his cardiologist. (Presumably, both a cardiologist or cardiovascular specialist and a urologist or oncologist would treat him.) He needs to ensure that all the providers have a discussion about what the best and safest treatment would be before therapy begins. Obviously, this trial (the PRONOUNCE trial regarding which is safer for patients with cardiovascular issues, the GnRH agonist Lupron or antagonist Firmagon (or neither?) https://tinyurl.com/yxnw5kb6) is not completed yet so we don’t have any answers. In the meantime, it is certainly in the patient’s best interest to ensure that his providers are communicating and trying to jointly determine the right approach.”

So much to be considered, but so important to do so.

Disclaimer: Please recognize that I am not a Medical Doctor. Rather, I do consider myself a medical detective. I have been an avid student researching and studying prostate cancer as a survivor and continuing for decades and has been shown to control disease and improving symptoms. In addition, for men with high-risk localized or locally advanced prostate cancer, short-course ADT in combination with radiotherapy improves survival. There is evidence that ADT increases cardiovascular risk, particularly in men with preexisting cardiovascular disease. This increased risk may apply even with short-course ADT. In an individual patient, the benefits of ADT should be balanced against the risk, and patients who require ADT should have risk factors for cardiovascular disease optimized. There is some
Health Seeking Behavior, Cost of Illness and Quality of Life of Patients with COPD among 35 Years & above Rural Population of Gurugram, Haryana

By Balbir Singh Deswal & Ankita Khokhar

SGT Medical College, Hospital & Research Institute

Abstract- Background: COPD is the 4th leading cause of death worldwide and predicted to be third by 2030. In India, COPD accounts for 7% of mortality and 3% DALYs loss.

Objective: The study undertaken to assess the health seeking behaviour and cost of illness of COPD and the influence of severity of the disease over the cost and the quality of life.

Materials and Methods: The study conducted in 115 patients aged 35 years and above, a rural population of Gurugram, Haryana. Cost of illness (direct and indirect costs) was calculated in Indian rupees from the expenditures of the hospital visits, pharmacotherapy, oxygen therapy, biochemical investigations, diagnostic procedures, physiotherapy and hospitalization due to acute exacerbations by patient interview and review of patient’s case history, medical and billing records. Quality of life of patients in Stage III and Stage IV COPD was estimated using St. George’s Respiratory Questionnaire (SGRQ) score. Data collected on structured schedule & analyzed.

Keywords: COPD, health behavior, medical cost, quality of life.

GJMR-F Classification: NLMC Code: WA 292
Health Seeking Behavior, Cost of Illness and Quality of Life of Patients with COPD among 35 Years & above Rural Population of Gurugram, Haryana

Balbir Singh Deswal α & Ankita Khokhar σ

Abstract- Background: COPD is the 4th leading cause of death worldwide and predicted to be third by 2030. In India, COPD accounts for 7% of mortality and 3% DALYs loss.

Objective: The study undertaken to assess the health seeking behaviour and cost of illness of COPD and the influence of severity of the disease over the cost and the quality of life.

Materials and Methods: The study conducted in 115 patients aged 35 years and above, a rural population of Gurugram, Haryana. Cost of illness (direct and indirect costs) was calculated in Indian rupees from the expenditures of the hospital visits, pharmacotherapy, oxygen therapy, biochemical investigations, diagnostic procedures, physiotherapy and hospitalization due to acute exacerbations by patient interview and review of patient’s case history, medical and billing records. Quality of life of patients in Stage III and Stage IV COPD was estimated using St. George’s Respiratory Questionnaire (SGRQ) score. Data collected on structured schedule & analyzed.

Results: Out of the total costs, highest spent on direct medical costs (91.02%), less on indirect (8.98%). Hospitalizations, associated co-morbidity, and length of stay increased the cost. The mean cost incurred by patients with stage II COPD was Rs.3179.62 ± 99.01 per visit to the hospital, stage III was Rs.16414.79 ± 8365.79 and stage IV was Rs.44077.16 ± 15686.21 per visit. As the severity of COPD increased both direct and indirect costs increased, and the quality of life of the life decreased significantly (P<0.05).

Conclusion: Since acute exacerbations are the main cause of hospitalization among COPD patients, strategies to prevent severe exacerbations could be very cost effective and may improve the quality of life.

Keywords: COPD, health behavior, medical cost, quality of life.

II. METHODOLOGY

The study was conducted among field practice area of PHC Garhi Harsaru of Gurugram for one year from Jan 2018 to Dec 2018. Presuming the prevalence of cases about 7% among 35 years & above form previous study, a sample size of the population was calculated using formula n=( Z_{a/2}^2 p (1-p)/d^2 where p is prevalence and relative precision of 10% with anticipated non-response 10%. Population of all 14 villages consisting of 7700 households under PHC Garhi Harsaru listed as per 2011 census, and seven villages selected by simple random sampling. Out of these seven villages, 700 households were selected by probability proportion to size (PPS) sampling methods. All the 1434 individuals above 35 years of age found in these households were examined to detect chronic obstructive pulmonary diseases. Case definition was subject suffering from cough with expectoration for three or more months in a year for not less than two years and breathlessness. Spirometry done to confirm the case & severity of the condition (Gold criteria). A total of 137 cases listed on screening, of which 115 were taken as a confirmed case of COPD as per case definition, spirometry & pulmonary medicine consultant advice.

Cost of illness, which included the direct medical and non-medical, and indirect costs, calculated in Indian Rupees from the expenditures of the hospital visits, pharmacotherapy, oxygen therapy given, laboratory tests, diagnostic procedures, physiotherapy and hospitalization due to acute exacerbations. Quality of life (QOL) of all patients of COPD was assessed using St. George’s Respiratory Questionnaire (SGRQ) Ver 2.3 after obtaining the necessary permission from the author. Data collected on structured schedule and analyzed using SPSS ver 22. Prior ethical clearance was taken from Institutional Ethical Committee.

As per the definitions of the GOLD criteria guidelines according to the severity of the disease taken as:
Stage I (Mild) - EV1/FVC<70%, FEV1 > 80%
Stage II (Moderate) – FEV1/FVC < 70%, 50% ≤ FEV1 < 80% predicted
Stage III (Severe) – FEV1/FVC < 70%, 30% ≤ FEV1 < 50% predicted
Stage IV (Very Severe) – FEV1/FVC<70%, FEV1 < 30% predicted or FEV1<50% predicted plus chronic respiratory failure and having stable co morbidity.

III. Results

The mean age of the study patients was 52.56 ± 11.78 years, and 55 (47.83 %) patients were in the age group of 35-50 years, followed by 21(18.20%) in 51-60 years and 39 (33.91%) patients in above 60 years. 71 (61.74%) were males & 44 (38.26%) were females.

Out of total 115 cases, 57(44.8%) patients were suffering from stage I & II COPD followed by 42 (40%) patients with stage III COPD and 16 (15.2%) with stage IV COPD.

Existing stable co-morbidities found in 43 patients (40.95%) of which, treated tuberculosis seen in 15 (14.28%) patients. Other co-morbidities like diabetes, hypertension, diabetes and hypertension and ischemic heart disease also accounted 3.0 to 5.71% each.

a) Health seeking behavior

Among all COPD patients, 87.83% seeks immediate medical help in case of any breathing discomfort while 12.7% neglected their ailment & did not take any medical advice. Of these 46.09% preferred allopathic, 42.61 % preferred the Indian system of medicine & 11.30 % preferred naturopathy. 36.52% utilized government system while 6.09% could go to qualified private doctor, 41.74 depended upon quacks & 15.65% chemist store.

b) The economic cost burden of COPD case

Out of the total costs, highest spent on direct medical costs (91.02%) and followed by indirect costs (8.98%) as depicted in Table I. Hospitalizations, associated co-morbidity and length of stay increased the cost. The mean cost spent by the patients with stage II COPD was Rs.3179.62 ± 99.01 per visit to the hospital, stage III was Rs.16414.79 ± 8365.79 and stage IV was Rs.44077.16 ± 15686.21 per visit (Table 2). All the patients suffering from stage I & II COPD were treated in the outpatient department. Out of 42 patients with stage III COPD, 29 (32.4%) hospitalized, and 13 (12.4%) treated in the outpatient department. Sixteen patients with stage IV COPD admitted in the inpatient wards of the Pulmonary Medicine Department.

The mean length of hospital stay was found to be 9 ± 1.2 days for stage III patients and 11.75 ± 2.5 days for stage IV patients. As the severity of the disease increased both the length of hospital stay as well as cost burden increased as shown in Table 3.

c) Quality of life of patients with stage III and stage IV COPD

The quality of life of inpatients was evaluated by using SGRQ. Out of 115 patients, 45 were inpatients, of which 29 were with stage III COPD and 16 with stage IV COPD. The mean SGRQ QOL score of the 115 patients was found to be 53.96 ± 10.38. The SGRQ QOL score of the stage III COPD patients was found to be 44.69 ± 9.27 and stage IV patients was 63.24 ± 11.49. As the severity of the disease increased the quality of life of COPD cases significantly decreased (p < 0.05).

Table 1: Economic cost burden of COPD case

<table>
<thead>
<tr>
<th>Total Annual expenditure (INR) on COPD</th>
<th>No. of COPD subject (%)</th>
<th>Mean expenditure/head</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 10000</td>
<td>31 (26.96%)</td>
<td></td>
</tr>
<tr>
<td>10001-20000</td>
<td>71 (61.74%)</td>
<td></td>
</tr>
<tr>
<td>≥ 20000</td>
<td>13 (11.30%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Annual direct Cost   = Rs. 13,477/- (91.01%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Annual Indirect cost = Rs. 1,327/- (8.99%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Annual total mean cost = Rs. 14, 804 /- (100%)</td>
</tr>
</tbody>
</table>

Table 2: Economic Costs as per the severity of COPD

<table>
<thead>
<tr>
<th>Cost category</th>
<th>Cost drivers</th>
<th>Stage I &amp; II (n=57) (mean cost in rupees per patient per hospital visit)</th>
<th>Stage III (n=42) (mean cost in rupees per patient per hospital visit)</th>
<th>Stage IV (n=16) (mean cost in rupees per patient per hospital visit)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct Medical</td>
<td>Practitioner</td>
<td>200</td>
<td>1776.5</td>
<td>3612.5</td>
</tr>
<tr>
<td>Cost</td>
<td>Hospitalization</td>
<td>0</td>
<td>5897.87</td>
<td>19450</td>
</tr>
<tr>
<td></td>
<td>Laboratory</td>
<td>1425</td>
<td>1549.78</td>
<td>1737.81</td>
</tr>
<tr>
<td></td>
<td>investigations</td>
<td>350</td>
<td>484.04</td>
<td>743.75</td>
</tr>
<tr>
<td></td>
<td>Arterial blood</td>
<td>375</td>
<td>2147.34</td>
<td>2668.75</td>
</tr>
<tr>
<td></td>
<td>gases</td>
<td>500</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td></td>
<td>Diagnostic</td>
<td>113.1</td>
<td>658.02</td>
<td>2232.47</td>
</tr>
<tr>
<td></td>
<td>procedures</td>
<td>1.78</td>
<td>27.12</td>
<td>70.31</td>
</tr>
<tr>
<td></td>
<td>Pulmonary</td>
<td>42.85</td>
<td>569.68</td>
<td>569.68</td>
</tr>
<tr>
<td></td>
<td>function tests</td>
<td>0</td>
<td>651.38</td>
<td>1181.25</td>
</tr>
<tr>
<td></td>
<td>Drugs</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
IV. Discussion

COPD represents a high health-care burden worldwide. The increasing prevalence and life-long duration of the illness in those affected translates into increased direct and indirect medical expenditures. The findings of the present study shed light on the comprehensive cost expenditure of patients with COPD. The data obtained from this study demonstrated a strong correlation between the total cost incurred by patients for COPD management and the severity of the disease and which is in concordance with those found in international literature.6, 7

The present study had demonstrated a positive relation between the presence of co-morbidities and an increase in the cost of illness. This is in consistent with the report given by Mary Geitona et al. which stated that there was a significant correlation between associated co-morbidities and increased cost.8

a) Health seeking behavior

In the present study, among all COPD patients, 87.83% seeks immediate medical help in case of any breathing discomfort while 12.7% neglected their ailment. Similar findings were reported by Grover et al. from their study.9 The cost of illness was found to be higher for patients in stages III and IV COPD as these patients were treated with more number of drugs both initially, during follow-up and also had more number of hospital visits due to frequent acute exacerbations, leading to greater use of diagnostic procedures which had also contributed to higher cost of illness.

The data obtained from the present study had shed light to the cost variables that contributed to the total cost of illness at different stages of COPD. In stage II COPD, biochemical investigations were the most important cost variable. In stage III & IV, costs of hospitalization, diagnostic procedures, physician and drugs were the most important cost variables. This was due to increase in length of hospital stay and antibiotic usage in severe stages of COPD. A similar report given by Daniel E Hilleman et al.10

The increase in severity of the disease has a dramatic negative impact on the quality of life of the patients, a significant decrease with an increase in SGRQ score. A multi centre 2-year follow up study by Claudio F Donner demonstrated that repeated exacerbations resulted in a permanent negative impact on health status.11

Patients with COPD experience poor physical functioning and live with distressing symptoms that require frequent hospitalization due to disease progression. They develop inability to work and may become socially isolated and often depressed. The current study had shown that the cost of illness increased as the quality of life of patients decreased. Quality of life worsened with severity of disease and with exacerbations resulting in more hospitalization and increased cost of treatment.12, 13 The focused on the decrease in health-related quality of life with an increase in cost of therapy in COPD.

b) Cost of illness of COPD

In the present study the direct cost was found to be 91% of the total cost. Majority of the amount was spent for hospitalization, laboratory investigations, diagnostic procedures, drugs and practitioner. This is in concordant with other studies.5, 13

On an average a patient spent around 15379.1 Rupees per visit to the hospital. The highest being spent for hospitalization (36.2%) followed by diagnostic procedures (9.8%), laboratory investigations (9.87%), for practitioner (9.21%), morbidity (8%), drugs (4.4%) and the rest accounted for 23.5% (Table 2). Out of the total costs
costs, highest was on direct medical costs (81.2%) followed by indirect costs to 8.98%. The mean amount spent by patients with stage II COPD Rs.3179.42 ± 99.01 per patient per visit; stage III Rs.16414.79 ± 8365.79 and stage IV Rs.44077.16 ± 15686.21 per patient per visit. The patients with stage IV spent nearly 13 times more than stage II and 2.3 times than stage III patients. In stage II a patient spent around 3179 rupees per hospital visit; the highest was spent for laboratory investigations, followed by pulmonary function tests, diagnostic procedures, arterial blood gases, practitioner charges and the rest of the cost drivers accounting to 330 rupees. In stage III a patient spent around Rs.16549 per hospital visit; the highest was spent for hospitalization (Rs.5897). Similarly in stage IV a patient spent around Rs.43852; the highest was spent for hospitalization (Rs.19450). As the disease severity increased, the amount for the illness also increased. The severity of disease highly correlated with cost of illness. Findings are concordant with their separate studies reported by Kallaru et al and Patel et al. 14-16

c) Quality of life of patients with stage III and stage IV COPD

The quality of life of inpatients was evaluated by using SGRQ. The mean SGRQ QOL score of the 115 patients was found to be 53.96 ± 10.38. The SGRQ QOL score of the stage III COPD patients was found to be 44.69 ± 9.27 and stage IV patients was 63.24 ± 11.49. As the severity of the disease increased the quality of life of COPD patients significantly decreased. Cost of the disease negatively correlated with quality of life. Quality of life was similarly found to be severely impaired in COPD patients by various studies. 17-19

V. Conclusion

The study demonstrated that the total cost of illness of COPD patients increased with severity of disease. The Quality of life of the patients decreased with increase in severity of the disease. The drivers of the total cost were found to be hospitalizations and length of stay. Since acute exacerbations are the main cause of hospitalization among COPD patients, strategies to prevent severe exacerbations could be very cost effective and improve the quality of life. By developing strategies to improve patients’ awareness on nicotine replacement therapy, adherence to drug therapy and opting for physical rehabilitation, the direct medical and indirect costs can be reduced which in turn will lower the burden of cost of illness of COPD.

Acknowledgement

Authors are thankful to the Head, Dept of Pulmonary Medicine, SGT Medical College, Hospital & Research Institute, Budhera, Gurugram Haryana, for necessary help for the study & management of COPD cases.

References Références Referencias


This page is intentionally left blank
Ratio of Zinc to Bromine, Iron, Rubidium, and Strontium Concentration in the Prostatic Fluid of Patients with Chronic Prostatitis

By Vladimir Zaichick & Sofia Zaichick
Northwestern University

Abstract- Introduction: The absence of robust and unambiguous diagnostic markers may at the present time allow the symptoms of chronic prostatitis to overlap with those of other conditions. The aim of this study was to evaluate whether significant changes in the ratios of Zn/Br, Zn/Fe, Zn/Rb, and Zn/Sr concentrations in prostatic fluid can aid in the recognition of an inflamed prostate.

Methods: Prostatic fluid levels of Br, Fe, Rb, Sr and Zn were prospectively evaluated in 33 patients with chronic prostatitis and also in 42 healthy males. Measurements were performed using 109Cd radionuclide-induced energy dispersive X-ray fluorescent microanalysis. The results allowed values of the Zn/Br, Zn/Fe, Zn/Rb, and Zn/Sr concentration ratios to be calculated.

Results: It was observed that in the inflamed prostates the ratios of Zn/Br, Zn/Fe, and Zn/Rb significantly decreased in a comparison with those normal prostates.

Keywords: chronic prostatitis; prostatic fluid; trace element concentrations; trace element concentration ratios; energy-dispersive x-ray fluorescent analysis.

GJMR-F Classification: NLMC Code: WJ 752

© 2019. Vladimir Zaichick & Sofia Zaichick. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License http://creativecommons.org/licenses/by-nc/3.0/, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ratio of Zinc to Bromine, Iron, Rubidium, and Strontium Concentration in the Prostatic Fluid of Patients with Chronic Prostatitis

Vladimir Zaichick & Sofia Zaichick

Abstract: Introduction: The absence of robust and unambiguous diagnostic markers may at the present time allow the symptoms of chronic prostatitis to overlap with those of other conditions. The aim of this study was to evaluate whether significant changes in the ratios of Zn/Br, Zn/Fe, Zn/Rb, and Zn/Sr concentrations in prostatic fluid can aid in the recognition of an inflamed prostate.

Methods: Prostatic fluid levels of Br, Fe, Rb, Sr and Zn were prospectively evaluated in 33 patients with chronic prostatitis and also in 42 healthy males. Measurements were performed using 109Cd radionuclide-induced energy dispersive X-ray fluorescent microanalysis. The results allowed values of the Zn/Br, Zn/Fe, Zn/Rb, and Zn/Sr concentration ratios to be calculated.

Results: It was observed that in the inflamed prostates the ratios of Zn/Br, Zn/Fe, and Zn/Rb significantly decreased in a comparison with those normal prostates.

Conclusion: The alterations in levels of Zn/Br, Zn/Fe, and Zn/Rb in the fluid of inflamed prostates indicate involvement of these trace elements in the etiology and pathogenesis of chronic prostatitis. It is therefore supposed that the appropriate changes of the ratios of Zn/Br, Zn/Fe, and Zn/Rb in prostatic fluid samples can be used as markers of chronic prostatitis.

Keywords: chronic prostatitis; prostatic fluid; trace element concentrations; trace element concentration ratios; energy-dispersive x-ray fluorescent analysis.

1. Introduction

The prostate gland is subject to various disorders and of them chronic prostatitis (CP) is a complex disease. CP causes a range of symptoms including pain, urinary problems, such as urgency and frequency, reduced quality of life and sexual dysfunction. About 35–50% of men are reported to be affected by symptoms suggesting CP during their lifetime (1,2). Etiology of CP is not fully understood and treatment is frequently unsuccessful (3,4). Fragmentary epidemiological evidence indicates that risk factors such as infection, autoimmunity, inflammation, excessive amounts of tumor-related proteins, imbalance of hormones and nutrition-related variables, including some trace elements (TE) as micronutrients, may be associated with CP (5). CP is characterized by a multifactorial pathogenesis, and the condition is defined on the basis of clinical presentation rather than clear diagnostic markers or findings (6). The absence of robust and unambiguous diagnostic markers may cause the CP symptoms to overlap with those of other conditions, such as benign prostatic hyperplasia and prostate and cancer (7).

Oxidative stress has significant involvement in the pathogenesis of CP (8). Oxidative stress is a result of the imbalance between reactive oxygen species and antioxidants, including some TE, in the body that can cause tissue and organ damage. TE, besides their antioxidant properties, have many other essential physiological functions such as maintenance and regulation of cell function, gene regulation, activation or inhibition of enzymatic reactions, and regulation of membrane function. Essential or toxic (mutagenic, carcinogenic) properties of TE depend on tissue-specific need or tolerance, respectively (9,10). Besides the total amounts of individual TE, ratios of several TE should be taken into account to allow for a more reliable description of both the individual TE and health status (9,11).

In our previous studies a significant involvement of Zn, 32 Ca, Mg, Rb and some other TE in the functions of the prostate were studied (12-22). One of the main functions of the prostate gland is the production of prostatic fluid (23). It contains a high concentration of Zn and elevated levels of Ca, Mg, Rb, and some other TE in comparison with those in serum and other fluids of the human body.

The first finding of remarkably high levels of Zn in human expressed prostatic fluid (EPF) was reported in the early 1960s (24). After analyzing EPF expressed from the prostates of 8 apparently healthy men aged 25-55 years it was found that Zn concentrations varied from 300 to 730 mg/L. After this finding several investigators have suggested that the measurement of Zn levels in EPF may be useful as a marker of abnormal prostate secretory function (25, 26). It promoted more detailed studies of the Zn concentrations in the EPF of healthy subjects and in those with different prostatic diseases, including CP (26, 27). A detailed review of these studies, reflecting the contradictions within accumulated data, was given in our earlier publication (27). Moreover, the method and apparatus for micro...
analysis of Br, Fe, Rb, Sr, and Zn in the EPF samples using energy dispersive X-ray fluorescence (EDXRF) activated by radiation from the radionuclide source 109Cd was developed by us (28).

Thus, data on changes of TE content in EPF of patients with CP are very important, because this can clarify our knowledge of CP pathogenesis and may prove useful as CP diagnostic markers. In the present study it was supposed that apart from total amounts of TE the ratios of Zn to some other TE content in EPF are likely to reflect a disturbance of prostate function. To our knowledge there are no published data on TE ratios in prostatic fluids.

This work had three aims. The first aim was to assess the Br, Fe, Rb, Sr, and Zn concentrations in the EPF samples obtained from apparently healthy persons and patients with CP using the 109Cd EDXRF micro method. The second aim was to evaluate the quality of these results and to compare them with published data. The last aim was to calculate the Zn/Br, Zn/Fe, Zn/Rb, Zn/Sr ratios and compare their values with those obtained from EPF samples from normal and inflamed prostate glands. All studies were approved by the Ethical Committees of the Medical Radiological Research Centre, Obninsk. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or 75 national research committee and with the 1964 Helsinki declaration and its later amendments, or with comparable ethical standards.

II. MATERIAL AND METHODS

Specimens of EPF were obtained from 42 men with apparently normal prostates (mean age ± Standard Deviation - 54±13 years, range 31-75 years) and from 33 males with CP (mean age 50±9 years, range 37-65 years) in the Urological Department of the Medical Radiological Research Centre using standard rectal massage procedure. The diagnosis of CP was made by qualified urologists and in all cases the CP diagnosis was confirmed by clinical examination and by cytological and bacteriological investigations of the EPF samples. Subjects were asked to abstain from sexual inter course for three days preceding the procedure Specimens of EPF were obtained in sterile containers which were appropriately labeled. Twenty µL (microliters) of fluid were taken in duplicate by micropipette from every specimen for TE analysis, while the rest of the fluid was used for cytological and bacteriological investigations. One 20 µL sample of the EPF was dropped on a 11.3 mm diameter disk made of thin, ash-free filter paper fixed on pieces of Scotch tape pieces and dried in an exsiccator at room temperature. Then the dried sample was covered with a 4 mm Dacron film and centrally pulled onto a Plexiglas cylindrical frame (28).

To determine concentration of the TE by comparison with known standard, aliquots of solutions of commercial, chemically pure compounds were used for calibration (29). The standard samples for calibration were prepared in the same way as the samples of prostate fluid. Because there were no available liquid Certified Reference Materials (CRM) ten sub-samples of the powdered CRM IAEA H-4 (animal muscle) were analyzed to estimate the precision and accuracy of results. Every CRM sub-sample weighing about 3 mg was applied to the piece of Scotch tape serving as an adhesive fixing backing. An acrylic stencil made in the form of a thin-walled cylinder with 11.3mm inner diameter was used to apply the sub-sample to the Scotch tape. The polished-end acrylic pestle which is a constituent of the stencil set was used for uniform distribution of the sub-sample within the Scotch tape surface restricted by the stencil inner diameter. When the sub-sample was slightly pressed to the Scotch adhesive sample, the stencil was removed. Then the sub-sample was covered with 4 mm Dacron film. Before the sample was applied, pieces of Scotch tape and Dacron film were weighed using an analytical balance. They were reweighed after the sample had been placed inside to determine the sub-sample mass precisely.

The facility for the radionuclide-induced energy dispersive X-ray fluorescence included an annular 109Cd source with an activity of 2.56 GBq, AsI (Li) detector with an electric cooler and a portable multi-channel analyzer combined with a PC, comprised the detection system. Its resolution was 270eV at the 6.4 keV line. The facility functioned as follows. Photons with energy 22.1 keV from the 109Cd source arrive at the surface of the specimen inducing the fluorescent Ka X-rays from TE. The fluorescence reaches the detector after passing through a 10 mm diameter collimator. Then the X-ray’s arrival is recorded. The duration of the measurements of Br, Fe, Rb, Sr, and Zn concentration for each sample was 60 min. The intensity of Ka-line of Br, Fe, Rb, Sr, and Zn for EPF samples and standards was estimated from a calculation the total area under the corresponding photo peak in the spectra.

All EPF samples for EDXRF were prepared in duplicate and mean values of TE contents were used in the final calculation. Using the Microsoft Office Excel programs, the summary of statistics, arithmetic mean, standard deviation, standard error of mean, minimum and maximum values, median, percentiles with 0.025 and 0.975 levels was calculated for TE concentrations and the Zn/Br, Zn/Fe, Zn/Rb, Zn/Sr ratios in the EPF of normal and CP prostates. The difference in the results between the two groups of samples (normal prostate and CP) was evaluated by the parametric Student's t-test and non-parametric Wilcoxon-Mann-Whitney U-test.
III. Results

Table 1 depicts our data for Br, Fe, Rb, Sr, and Zn mass fractions in ten sub-samples of certified reference material (CRM) IAEA H-4 (animal muscle) and the certified values of this material.

Table 1: EDXRF data of Br, Fe, Rb, Sr, and Zn contents in the CRM IAEA H-4 (animal muscle) reference material compared to certified values (mg/kg, dry mass basis)

<table>
<thead>
<tr>
<th>Element</th>
<th>Certified values</th>
<th>This</th>
<th>M±SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fe</td>
<td>49</td>
<td>47-51</td>
<td>C</td>
</tr>
<tr>
<td>Zn</td>
<td>86</td>
<td>83-90</td>
<td>C</td>
</tr>
<tr>
<td>Br</td>
<td>4.1</td>
<td>3.5-4.7</td>
<td>C</td>
</tr>
<tr>
<td>Rb</td>
<td>18</td>
<td>17-20</td>
<td>C</td>
</tr>
<tr>
<td>Sr</td>
<td>0.1</td>
<td>-</td>
<td>N</td>
</tr>
</tbody>
</table>

Mean – arithmetical mean, SD – standard deviation, C- certified values, N – non-certified values.

The contents of four TE (Br, Fe, Rb, and Zn) were determined. These TE have certified values for the CRM IAEA H-4 (animal muscle) (Table 1). Mean values (M±SD) for Br, Fe, Rb, and Zn were in the range of the 95% confidence interval. Good agreement of the TE contents analyzed by 109Cd radionuclide-induced EDXRF with the certified data of CRM IAEA H-4 (Table 1) indicate an acceptable accuracy of the results obtained in the study of the prostatic fluid presented in Tables 2-4.

Table 2 presents certain statistical parameters (arithmetic mean, standard deviation, standard error of mean, minimal and maximal values, median, percentiles with 0.025 and 0.975 levels) of the Br, Fe, Rb, Sr, and Zn concentrations as well as of the Zn/Br, Zn/Fe, Zn/Rb, Zn/Sr ratios in EPF of normal and CP prostates.

The comparison of our results with published data for Br, Fe, Rb, Sr, and Zn concentrations and also for the Zn/Br, Zn/Fe, Zn/Rb, Zn/Sr ratios in EPF of normal and CP prostate. [26, 27, 30-32] is shown in Table 3.

The ratios of means and the differences between mean values of Zn/Br, Zn/Fe, Zn/Rb, Zn/Sr ratios in EPF of normal and CP prostate are presented in Table 4.

Table 2: Some basic statistical parameters of Br, Fe, Rb, Sr, and Zn concentration (mg/L) and Zn/Br, Zn/Fe, Zn/Rb, Zn/Sr concentration ratios in prostate fluid of healthy men and patients with chronic prostatitis

<table>
<thead>
<tr>
<th>Condition of prostate</th>
<th>Element or ratio</th>
<th>M</th>
<th>SD</th>
<th>SEM</th>
<th>Min</th>
<th>Max</th>
<th>Median</th>
<th>Per. 0.025</th>
<th>Per. 0.975</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norm</td>
<td>Br</td>
<td>2.81</td>
<td>2.88</td>
<td>0.57</td>
<td>0.490</td>
<td>8.53</td>
<td>1.26</td>
<td>0.496</td>
<td>8.53</td>
</tr>
<tr>
<td>31-75 years n=42</td>
<td>Fe</td>
<td>8.29</td>
<td>7.49</td>
<td>1.37</td>
<td>1.27</td>
<td>39.8</td>
<td>7.47</td>
<td>1.29</td>
<td>22.9</td>
</tr>
<tr>
<td></td>
<td>Rb</td>
<td>1.15</td>
<td>0.51</td>
<td>0.09</td>
<td>0.376</td>
<td>2.45</td>
<td>1.05</td>
<td>0.424</td>
<td>2.38</td>
</tr>
<tr>
<td></td>
<td>Sr</td>
<td>1.17</td>
<td>0.83</td>
<td>0.16</td>
<td>0.400</td>
<td>3.44</td>
<td>1.15</td>
<td>0.400</td>
<td>3.19</td>
</tr>
<tr>
<td></td>
<td>Zn</td>
<td>559</td>
<td>204</td>
<td>32</td>
<td>253</td>
<td>948</td>
<td>549</td>
<td>254</td>
<td>941</td>
</tr>
<tr>
<td></td>
<td>Zn/Br</td>
<td>624</td>
<td>603</td>
<td>118</td>
<td>43</td>
<td>1882</td>
<td>374</td>
<td>48</td>
<td>1882</td>
</tr>
<tr>
<td></td>
<td>Zn/Fe</td>
<td>117</td>
<td>96</td>
<td>18</td>
<td>13.0</td>
<td>343</td>
<td>77.0</td>
<td>17.0</td>
<td>343</td>
</tr>
<tr>
<td></td>
<td>Zn/Rb</td>
<td>628</td>
<td>369</td>
<td>67</td>
<td>119</td>
<td>1612</td>
<td>534</td>
<td>196</td>
<td>1513</td>
</tr>
<tr>
<td></td>
<td>Zn/Sr</td>
<td>750</td>
<td>539</td>
<td>104</td>
<td>155</td>
<td>2321</td>
<td>619</td>
<td>167</td>
<td>2015</td>
</tr>
<tr>
<td>Prostatitis</td>
<td>Br</td>
<td>3.35</td>
<td>2.64</td>
<td>0.69</td>
<td>0.120</td>
<td>9.85</td>
<td>2.98</td>
<td>0.201</td>
<td>8.73</td>
</tr>
<tr>
<td>37-65 years n=33</td>
<td>Fe</td>
<td>10.9</td>
<td>9.6</td>
<td>2.3</td>
<td>3.85</td>
<td>41.9</td>
<td>6.97</td>
<td>4.06</td>
<td>35.6</td>
</tr>
<tr>
<td></td>
<td>Rb</td>
<td>2.32</td>
<td>1.13</td>
<td>0.30</td>
<td>0.730</td>
<td>4.54</td>
<td>1.75</td>
<td>0.935</td>
<td>4.34</td>
</tr>
<tr>
<td></td>
<td>Sr</td>
<td>1.57</td>
<td>1.36</td>
<td>0.79</td>
<td>0.210</td>
<td>2.93</td>
<td>1.58</td>
<td>0.279</td>
<td>2.86</td>
</tr>
<tr>
<td></td>
<td>Zn</td>
<td>382</td>
<td>275</td>
<td>48</td>
<td>62.0</td>
<td>1051</td>
<td>295</td>
<td>75.0</td>
<td>950</td>
</tr>
<tr>
<td></td>
<td>Zn/Br</td>
<td>129</td>
<td>96</td>
<td>32</td>
<td>14.1</td>
<td>322</td>
<td>103</td>
<td>20.2</td>
<td>298</td>
</tr>
<tr>
<td></td>
<td>Zn/Fe</td>
<td>35.9</td>
<td>20.6</td>
<td>5.3</td>
<td>7.03</td>
<td>66.3</td>
<td>33.7</td>
<td>9.12</td>
<td>66.0</td>
</tr>
<tr>
<td></td>
<td>Zn/Rb</td>
<td>175</td>
<td>101</td>
<td>29</td>
<td>41.3</td>
<td>381</td>
<td>154</td>
<td>48.8</td>
<td>367</td>
</tr>
<tr>
<td></td>
<td>Zn/Sr</td>
<td>484</td>
<td>732</td>
<td>422</td>
<td>34.6</td>
<td>1329</td>
<td>88.2</td>
<td>37.3</td>
<td>1267</td>
</tr>
</tbody>
</table>

M - Arithmetic mean, SD – Standard deviation, SEM – Standard error of mean, Min – Minimum value, Max – Maximum value, Per. 0.025 – Percentile with 0.025 level, Per. 0.975 – Percentile with 0.975 level.
Table 3: Median, minimum and maximum value of means of Fe, Zn, Br, Rb, and Sr concentration (mg/L) as well as of Zn/Br, Zn/Fe, Zn/Rb, and Zn/Sr ratio in prostate fluid of health men and patients with prostatitis according to data from the literature

<table>
<thead>
<tr>
<th>Condition</th>
<th>Element or ratio</th>
<th>Published data [Reference]</th>
<th>This work results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Median of means (n)*</td>
<td>Minimum of means M or M±SD, (n)**</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norm</td>
<td>Br</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Fe</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Rb</td>
<td>1.11 (1)</td>
<td>1.11±0.57 (15) [26]</td>
</tr>
<tr>
<td></td>
<td>Sr</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Zn</td>
<td>453 (19)</td>
<td>47.1(-) [30]</td>
</tr>
<tr>
<td></td>
<td>Zn/Br</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Zn/Fe</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Zn/Rb</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Zn/Sr</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Prostatitis</td>
<td>Br</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Fe</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Rb</td>
<td>2.26 (1)</td>
<td>2.26±1.28 (18) [26]</td>
</tr>
<tr>
<td></td>
<td>Sr</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Zn</td>
<td>222 (7)</td>
<td>88.9 (29) [32]</td>
</tr>
<tr>
<td></td>
<td>Zn/Br</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Zn/Fe</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Zn/Rb</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Zn/Sr</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

M - Arithmetic mean, SD – Standard deviation, (n)* – Number of all references, (n)** - Number of samples.

Table 4: Comparison of mean values (M±SEM) of Fe, Zn, Br, Rb, and Sr concentrations (mg/L) as well as of Zn/Br, Zn/Fe, Zn/Rb, and Zn/Sr ratios in prostate fluid of healthy men and patients with chronic prostatitis

<table>
<thead>
<tr>
<th>Element or ratio</th>
<th>Age groups</th>
<th>Ratios</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Norm</td>
<td>Prostatitis</td>
</tr>
<tr>
<td>Br</td>
<td>2.81±0.57</td>
<td>3.35±0.69</td>
</tr>
<tr>
<td>Fe</td>
<td>8.29±1.37</td>
<td>10.9±2.3</td>
</tr>
<tr>
<td>Rb</td>
<td>1.15±0.09</td>
<td>2.32±0.30</td>
</tr>
<tr>
<td>Sr</td>
<td>1.17±0.16</td>
<td>1.57±0.79</td>
</tr>
<tr>
<td>Zn</td>
<td>559±32</td>
<td>382±48</td>
</tr>
<tr>
<td>Zn/Br</td>
<td>624±118</td>
<td>129±32</td>
</tr>
<tr>
<td>Zn/Fe</td>
<td>117±18</td>
<td>35.9±5.3</td>
</tr>
<tr>
<td>Zn/Rb</td>
<td>628±67</td>
<td>175±29</td>
</tr>
<tr>
<td>Zn/Sr</td>
<td>750±104</td>
<td>484±422</td>
</tr>
</tbody>
</table>

M – Arithmetic mean, SEM – Standard error of mean, *Wilcoxon-Mann-Whitney U-test, bold – Significant difference (p≤0.05).

In the EPF samples of CP prostates our results were comparable with published data for Zn concentrations (Table 3). No published data referring to Br, Fe, Rb, and Sr concentrations, as well as to Zn/Br, Zn/Fe, Zn/Rb, Zn/Sr ratios in EPF samples obtained from patients with CP, were found.

In the cited literature a number of values for Zn concentrations in normal EPF were not expressed on a wet mass basis. Therefore, we calculated these values using the published data for water –93.2% (33).

From Table 4, it is observed that in the EPF of CP prostates the ratios of Zn/Br, Zn/Fe, and Zn/Rb are almost 5, 3, and 4 times, respectively, lower than levels of these ratios in EPF of normal prostates.

The range of means of Zn concentration reported in the literature for normal EPF (from 47.1 to 5185 mg/L) and for EPF of untreated CP prostate (from 88.9 to 564 mg/L) varies widely (Table 3). This can be explained by a dependence of Zn content on many factors, including age, ethnicity, mass of the gland, presence of benign prostatic hyperplasia, and others. These factors were not controlled in the cited studies. Another and, in our opinion, leading cause of interobserver variability was insufficient quality control of
results in these studies. In many reported papers EPF samples were dried at high temperature or with acid digestion. There is evidence that by use of these treatment methods some quantities of trace elements, including Zn, are lost as a result of this treatment (34-36).

Characteristically, elevated or deficient levels of TE and electrolytes observed in EPF are discussed in terms of their potential role in etiology of diseases. In our opinion, abnormal levels of some TE and their ratios in EPF of CP prostate could be the consequence of inflammation. Compared to other fluids of the human body, the prostate secretion contains higher levels of Zn and some other TE. These data suggest that these TE could be involved in functional aspects of the prostate. Inflammation is accompanied by a suppression of specific functional activities of prostatic cells, which leads to a small reduction in the Zn content in EPF. Why Br, Fe, Sr, and particularly Rb content increase in the EPF of CP prostate and how it acts on the gland are still to be fully understood.

Our findings show that the concentration of Br, Fe, Sr, and particularly Rb increased whereas the concentration of Zn is somewhat decreased in the EPF of CP prostate as compared to their levels in EPF of normal prostates (Table 4). Our present results have formed the basis for a new method for diagnosis of CP, the essence of which will be evaluation of the ratios of formed the basis for a new method for diagnosis of CP, normal prostates (Table 4). Our present results have formed the basis for a new method for diagnosis of CP, normal prostates. In our opinion, abnormal levels of some TE and their ratios in CP prostates as compared to their levels in EPF of normal prostates. It was observed that in the EPF of CP prostates the ratios of Zn/Br, Zn/Fe, and Zn/Rb decreased in a comparison with those in the EPF of normal prostates. In our opinion, the observed alterations in levels of Zn/Br, Zn/Fe, and Zn/Rb ratios in the EPF of inflamed prostates demonstrate an involvement of these trace elements in the etiology and pathogenesis of CP. So it is presumed that the changes in the Zn/Br, Zn/Fe, and Zn/Rb ratios in the EPF samples can be used as markers of the presence of CP.

ACKNOWLEDGEMENT

Authors are grateful to Dr Tatyana Sviridova, Medical Radiological Research Center, Obninsk for supplying EPF samples. The authors are also grateful to Dr. Sinclair Wynchank for a very valuable and detailed discussion of the results of this work and his help in English.

REFERENCES

8. Ihsan A U, Khan F U, Khongorzul P, et al. Role of oxidative stress in pathology of chronic prostatitis/chronic pelvic pain syndrome and male

IV. Conclusion

In this work, TE measurements were carried out in the EPF samples of normal and CP prostates using the non-destructive instrumental EDXRF micro method developed by us. It was shown that this method is an adequate analytical tool for the non-destructive determination of Br, Fe, Rb, Sr, Zn concentration and also ratios of some of these TE in the EPF samples of human prostates. It was observed that in the EPF of CP prostates the ratios of Zn/Br, Zn/Fe, and Zn/Rb decreased in a comparison with those in the EPF of normal prostates. In our opinion, the observed alterations in levels of Zn/Br, Zn/Fe, and Zn/Rb ratios in the EPF of inflamed prostates demonstrate an involvement of these trace elements in the etiology and pathogenesis of CP. So it is presumed that the changes in the Zn/Br, Zn/Fe, and Zn/Rb ratios in the EPF samples can be used as markers of the presence of CP.
34. Zaichick V. Sampling, sample storage and preparation of biomaterials for INAA in clinical medicine, occupational and environmental health. In: Harmonization of Health-Related Environmental


Assessment of Knowledge and Associated Risk Factors Regarding Zoonotic Disease among Community Members of Siddharthanagar Municipality, Bhairahawa, Rupandehi

By Subash Rimal, Asmita Shrestha, Rabina Ghimire & Dr. Arjun Chapagain

Tribhuvan University

Abstract- Zoonoses are the common cause of disease occurrence in animals and humans in Bhairahawa. Many zoonotic disease such as Tuberculosis, Rabies, Heartworm, Brucella, Leptospira has been encountered in Veterinary Teaching Hospital, Institute of Agriculture and Animal Science (IAAS), Tribhuvan University from Bhairahawa periphery. We conducted a cross-sectional purposive random survey of total 303 villagers of Siddharthanagar Municipality, Bhairahawa, Rupandehi to study awareness status about zoonosis. Out of total individuals interviewed, 176 (58%) heard about the zoonotic disease and radio/television (37.5%) were the source of information. 66.7% female and 56.9% male knew about zoonosis. 72.9% of youths (30-50 years), 36.6% farmers, 33.33% Dalit and 40.2% Madheshi, 58.6% Hindu, 66.7% Buddhist, 66.7% of Christian knew about zoonosis. 86% of aware people knew about direct transmission rout of zoonotic disease, and 100%, 77.84%, 100%, 100% and 47.72% respondents knew about the contaminated food, milk, meat, bite, and secretion transmission route respectively.

Keywords: survey, zoonoses, siddharthanagar, veterinary teaching hospital, bhairahawa.

GJMR-F Classification: NLMC Code: WC 302
Assessment of Knowledge and Associated Risk Factors Regarding Zoonotic Disease among Community Members of Siddharthanagar Municipality, Bhairahawa, Rupandehi

Subash Rimal, Asmita Shrestha, Rabina Ghimire & Dr. Arjun Chapagain

Abstract- Zoonoses are the common cause of disease occurrence in animals and humans in Bhairahawa. Many zoonotic disease such as Tuberculosis, Rabies, Heartworm, Brucella, Leptospira has been encountered in Veterinary Teaching Hospital, Institute of Agriculture and Animal Science (IAAS), Tribhuvan University from Bhairahawa periphery. We conducted a cross-sectional purposive random survey of total 303 villagers of Siddharthanagar Municipality, Bhairahawa, Rupandehi to study awareness status about zoonosis. Out of total individuals interviewed, 176 (58%) heard about the zoonotic disease and radio/television (37.5%) were the source of information. 66.7% female and 56.9% male knew about zoonosis. 72.9% of youths (30-50 years), 36.6% farmers, 33.33% Dalit and 40.2% Madheshi, 58.6% Hindu, 66.7% Buddhist, 66.7% of Christian knew about zoonosis. 86% of aware people knew about direct transmission route of zoonotic disease, and 100%, 77.84%, 100%, 100% and 47.72% respondents knew about the contaminated food, milk, meat, bite, and secretion transmission route respectively. Age, education, ethnicity, occupation play highly significant (P<0.05) effect on zoonosis, where religion had significant (P<0.05) effect but sex had no significant relationship. Hence our study suggests that zoonotic disease pose a threat to people but the risk grossly underestimated.

Keywords: survey, zoonoses, siddharthanagar, veterinary teaching hospital, bhairahawa.

I. Introduction

a) Background

Zoonoses caused by infection that spread between animal and people. Of the known pathogen species implicated in human disease, 61% are zoonotic. Comparatively neglected among this vast group of pathogens are endemic zoonoses. Many endemic zoonoses not only cause considerable human disability but also impair livestock productivity, imposing multiple burdens on poor communities. Developing and under developed countries are being comparatively more affected by these zoonotic diseases due to lack of proper education on zoonoses, awareness, and improper management of farms (Chowdhury et. al., 2018). And this situation is alarming.

b) Statement of problem

Zoonoses are the common cause of disease occurrence in animals and humans in Bhairahawa. There are large numbers of dog bites cases admitted to veterinary hospitals as well as a human hospital of Bhairahawa. Rabies, Tuberculosis, Brucellosis, Echinococcus, Heartworm, Leptospirosis are most zoonoses encountered on Veterinary Teaching Hospital, IAAS Paklihawa. These all disease has zoonotic importance, but many people are unknown about these diseases which have a high risk of transmission. The exact status of zoonotic disease and its consequences have not been access in Nepal. Since humans share their environment with animals, it was decided to study the level of awareness among humans regarding some of the zoonotic diseases spread by animals.

c) Rationale of study

The major rationale of this study is to assess the level of awareness among the farmers, risk factors associated with the zoonoses and concerned personnel. This study also aims to assess the zoonotic risks associated with infected animals and help to make policy about awareness of zoonoses because this study provides status and conditions of awareness about zoonoses around the Bhairahawa periphery.
d) Objectives

i. General objectives
To assess the knowledge and associated risk factors regarding the zoonotic disease among community members of Siddharthanagar Municipality, Bhairahawa, Rupandehi.

ii. Specific objectives
- To assess the effect of sex, age, ethnicity, education on zoonoses.
- To assess the mode of transmission and other factors in zoonoses.

II. Methods and Methodology

a) Study area
Siddharthanagar (formerly Bhairahawa) municipality is the administrative headquarter of Rupandehi District on the Outer Terai plains of Nepal, 265 km (165 mi) west of Kathmandu Nepal's capital. It is also the "Gateway of Lumbini," Lumbini, the birthplace of Gautama Buddha is 25 km to the west. It borders India, Sonauli in Maharajganj district of Uttar Pradesh. This study were conducted at Bhairahawa periphery, Siddharthanagar Municipality, Rupandehi Nepal.

b) Study design
A cross-sectional purposive sampling was conducted with irrespective of; age, sex, cast, were done by stratified random sampling method.

c) Sample size
The Sample size were estimated by using ausvetEpitools epidemiological calculators assuming:
Estimated Proportion=0.3, Desired precision of estimate= 0.05, Confidence level= 0.95 and Population size of Siddharthanagar municipality was 163483 in 2011. By this way, the sample size was 323, but only 303 villagers were selected in the study.

d) Methods
A total of 303 villagers were selected randomly from Siddharthanagar Municipality, Bhairahawa, Nepal and interviewed with a questionnaire containing both open- and close-ended questions on various aspects of zoonotic diseases and test their knowledge and awareness about zoonotic diseases. The questionnaire contains general zoonoses knowledge; reported a recent experience of zoonoses cases; knowledge of signs and symptoms of selected zoonoses in humans and animals; knowledge of zoonoses transmission; and testing, prevention, and treatment practices, etc. The section assessing knowledge of disease symptoms and signs consisted of a series of closed (yes/no response) questions asking whether a particular symptom or sign was commonly associated with each disease. Listed symptoms and signs included those commonly associated with each named disease as well as others not typically associated with any of these diseases.

III. Statistical Analysis
The data were collected, coded and tested by using SPSS-tools and were analyzed by chi-square test and descriptive analysis was done by using MS-excel.

IV. Result
Total 303 individuals of Siddharthanagar Municipality, Rupandehi were interviewed for assessing the knowledge and associated risk factors regarding zoonotic disease among community members of Siddharthanagar Municipality, Bhairahawa, Rupandehi.

a) Descriptive Analysis
i. Heard about zoonosis and their source of knowledge
Out of total individuals interviewed 176 (58%) have heard about zoonotic disease whereas 127 (42%) have not.

![Heard about zoonosis](image)

Among the individuals who have heard about zoonosis, 66 (37.5%) have it from Radio/TV, six from printed materials, 13 have from both Radio/TV and printed materials and six from more than two sources above.
ii. **Age**

Individuals of age group 30-50 years were mostly interviewed. Among them, 72.9% know about zoonotic disease followed by individuals of age group 16-30 years, i.e., 71.8% with least knowledge in individuals of age group 50-70 years.

### Table 1: Different age group with knowledge about zoonosis

<table>
<thead>
<tr>
<th>Age of respondent</th>
<th>Do you know about zoonotic disease</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% Within age of respondent</td>
<td></td>
</tr>
<tr>
<td>16-30 yrs</td>
<td>Yes</td>
<td>71.8%</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>28.2%</td>
</tr>
<tr>
<td>30-50 yrs</td>
<td>Yes</td>
<td>72.9%</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>27.1%</td>
</tr>
<tr>
<td>50-70 yrs</td>
<td>Yes</td>
<td>21.2%</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>78.8%</td>
</tr>
</tbody>
</table>

iii. **Gender**

267 male and 36 female were interviewed. Among total males, 152 (56.9%) have heard about zoonosis, and among total females, 24 (66.7%) have heard about it.
iv. Occupation

People involved in agriculture (115/303) were mostly interviewed. However, only 42 (36.5%) have heard about zoonosis.

<table>
<thead>
<tr>
<th>Occupation of Respondent</th>
<th>Do you know about zoonotic disease</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Agriculture</td>
<td>42</td>
<td>73</td>
</tr>
<tr>
<td>% within occupation of respondent</td>
<td>36.5%</td>
<td>63.5%</td>
</tr>
<tr>
<td>Business</td>
<td>60</td>
<td>30</td>
</tr>
<tr>
<td>% within occupation of respondent</td>
<td>66.7%</td>
<td>33.3%</td>
</tr>
<tr>
<td>Government Job</td>
<td>19</td>
<td>0</td>
</tr>
<tr>
<td>% within occupation of respondent</td>
<td>100.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Non Government</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>% within occupation of respondent</td>
<td>0.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td>Abroad</td>
<td>12</td>
<td>6</td>
</tr>
<tr>
<td>% within occupation of respondent</td>
<td>66.7%</td>
<td>33.3%</td>
</tr>
</tbody>
</table>
Assessment of Knowledge and Associated Risk Factors Regarding Zoonotic Disease among Community Members of Siddharthanagar Municipality, Bhairahawa, Rupandehi

<table>
<thead>
<tr>
<th>Count</th>
<th>18</th>
<th>12</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>% within occupation of respondent</td>
<td>60.0%</td>
<td>40.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td>Count</td>
<td>25</td>
<td>0</td>
<td>25</td>
</tr>
<tr>
<td>% within occupation of respondent</td>
<td>100.0%</td>
<td>0.0%</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

v. Ethnicity
Individuals from Madhesi Community (122/303) were mostly interviewed. However, only 49 (40.2%) have heard about zoonosis.

![Ethnicity with knowledge about zoonosis](image)

**Table 4: Ethnicity with knowledge about zoonosis**

<table>
<thead>
<tr>
<th>Ethnicity of respondent</th>
<th>Do you know about zoonotic disease</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Brahmin</td>
<td>48</td>
<td>6</td>
</tr>
<tr>
<td>% Within ethnicity of respondent</td>
<td>88.9%</td>
<td>11.1%</td>
</tr>
<tr>
<td>Chhetri</td>
<td>19</td>
<td>0</td>
</tr>
<tr>
<td>% Within ethnicity of respondent</td>
<td>100.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Janajati</td>
<td>54</td>
<td>30</td>
</tr>
<tr>
<td>% Within ethnicity of respondent</td>
<td>64.3%</td>
<td>35.7%</td>
</tr>
<tr>
<td>Madhesi</td>
<td>49</td>
<td>73</td>
</tr>
<tr>
<td>% Within ethnicity of respondent</td>
<td>40.2%</td>
<td>59.8%</td>
</tr>
<tr>
<td>Dalit</td>
<td>6</td>
<td>12</td>
</tr>
<tr>
<td>% Within ethnicity of respondent</td>
<td>33.3%</td>
<td>66.7%</td>
</tr>
<tr>
<td>Others</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>% Within ethnicity of respondent</td>
<td>0.0%</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

vi. Education Level
Respondents were mostly educated at and upto primary level (84/303). Illiterate people have the least knowledge about zoonosis i.e., only 12 (38.7%) whereas all respondents (100%) from Bachelor’s and above have heard about zoonosis.
vii. Religion

Most of the respondents were Hindu (249/303). Among Hindu, 146 (58.6%) have heard about zoonosis.
viii. People in household
Most of the respondents have a family size of 4 (181/303) followed by the family size of 4 to 6 (79/303) and 6 to 10 (43/303).

ix. Transmission of zoonotic disease
a. Direct Transmission
Out of total of 176 individuals who have heard about zoonosis, 86% thinks that transmits directly from animal to human.
Assessment of Knowledge and Associated Risk Factors Regarding Zoonotic Disease among Community Members of Siddharthanagar Municipality, Bhairahawa, Rupandehi

**2019**

Global Journal of Medical Research  Volume XIX  Issue IV  Version I

**Fig. 10:** Knowledge in people regarding the direct transmission of zoonosis

b. **Contaminated food**
   Out of 176 individuals, 100% thinks that zoonosis transmit through contaminated food.

c. **Milk Transmission**
   Out of 176 individuals, 137 (77.84%) thinks that zoonotic disease could be transmitted through the consumption of milk from the infected animals.

**Fig. 11:** Knowledge in people regarding the transmission of zoonosis through the milk

d. **Meat Transmission**
   Out of 176 individuals, 100% assumes that zoonosis transmits through the contaminated food.

e. **Bite Transmission**
   Out of 176 individuals, 100% assumes that zoonosis transmits through the bite of an infected animal.

**Fig. 12:** Knowledge in people regarding the transmission of zoonosis through secretion

f. **Secretion Transmission**
   Out of 176 individuals, 84 thinks zoonosis can transmit through secretion of an infected animal.
x. **Zoonotic disease from animal**

![Figure 13: Zoonotic disease from animal](image1)

xi. **Family Affected by zoonotic animal**

![Figure 14: Family affected by zoonotic animal](image2)

xii. **Heard of any zoonotic disease**

![Figure 15: Heard of any zoonotic disease](image3)

b) **Statistical Analysis**

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Description</th>
<th>( \chi^2 ) value</th>
<th>p-value</th>
<th>Significant or Non-Significant</th>
<th>Cramer’s V value</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Age of Respondent</td>
<td>66.136</td>
<td>0.000</td>
<td>Very Highly Significant</td>
<td>0.467</td>
<td>Medium effect</td>
</tr>
<tr>
<td>2.</td>
<td>Gender of respondent</td>
<td>1.236</td>
<td>0.266</td>
<td>Non-significant</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3.</td>
<td>Occupation of Respondent</td>
<td>65.341</td>
<td>0.000</td>
<td>Very Highly Significant</td>
<td>0.464</td>
<td>Medium effect</td>
</tr>
<tr>
<td>4.</td>
<td>Ethnicity of Respondent</td>
<td>65.021</td>
<td>0.000</td>
<td>Very Highly Significant</td>
<td>0.463</td>
<td>Medium effect</td>
</tr>
<tr>
<td>5.</td>
<td>Educational status of respondent</td>
<td>65.341</td>
<td>0.000</td>
<td>Very Highly Significant</td>
<td>0.464</td>
<td>Medium effect</td>
</tr>
<tr>
<td>6.</td>
<td>Religion of respondent</td>
<td>8.935</td>
<td>0.30</td>
<td>Significant</td>
<td>0.172</td>
<td>Weak effect</td>
</tr>
</tbody>
</table>
V. Discussion

In our study, out of total individuals interviewed 58% have heard about zoonotic disease whereas 42% haven’t heard about the zoonotic disease. This result is lower than Singh et al., 2019; Wario et al., 2018; Ozioko et al., 2018. The lower level of knowledge regarding zoonoses is likely to cause exposure at increased risks to these diseases.

Television and radio are the source of information to most respondents who know about zoonosis accounting to 37.5%. This might be due to the easy access to radio and television.

Age of respondent significantly influenced the knowledge about zoonosis (p=0.000). The people of higher age group ie, above 50 years had less about zoonosis compared to the lower age group. This might be because younger people are more educated than, the older age group.

267 male and 36 female household were interviewed, but only 56.9% male have heard about zoonosis, and 66.7% female have about it but the results were statistically non-significant. Males are at a higher risk of zoonotic disease transmission due to their occupational exposure.

Respondents were mostly educated up to primary level. Illiterate people have the least knowledge about zoonosis ie, only 38.7% whereas all respondents 100% from Bachelor’s, and above have heard about zoonosis. The educational status of respondents showed a highly significant difference (p=0.000) responding to the knowledge about zoonosis. The lower level of knowledge about zoonosis is due to a low level of education level in people.

People with a different occupation were interviewed, among which people involved in agriculture were mostly interviewed. However, only 36.5% of the agricultural respondents knew about zoonotic diseases. Knowledge about zoonosis was significantly affected by the occupation of respondents (p=0.000). Livestock and animal holders are more at risk of zoonosis due to their close contact with animals, but due to lack of awareness among them, they may contract these diseases. All students interviewed knew about zoonotic diseases.

Most of our respondents consist of Madhesi ethnicity, and there is a low level of zoonotic knowledge among them. Also, the dalit community had a lower level of regarding zoonosis. Other ethnic groups like Brahmin, Chhetri, Janjati were comparatively more aware of the diseases. The result was statistically significant (p=0.000). Siddharthanagar municipality consists of more Madhesi community. The lower level of awareness among these communities may be due to the lower level of literacy and marginalized living standard. They are at more risk of contracting zoonotic diseases.

In this study, 86%, 100%, 77.84%, 100%, 100% and 47.72% respondents who know about zoonotic diseases think that zoonotic disease can be transmitted directly from animal to man, through contaminated food, milk, meat, bite, and secretion respectively. Most respondents knowing about zoonotic diseases are aware that the transmission takes place in different ways. This awareness is likely to decrease the risk of contracting zoonotic diseases, and they can take proper precautions.

Many respondents knew that zoonotic disease were transmitted from dogs, and cats and less of them knew about transmission through other animals. Majority of the respondents knew that rabies is transmitted by the bite of the dog. People are aware about vaccination against rabies after any dog bite. Out of the respondents interviewed, four people’s family have been previously affected with the zoonotic disease.

VI. Conclusion

This study suggests that the zoonotic disease pose a threat to people, but the risks were grossly underestimated. Despite the risks possessed by the zoonotic diseases, only a few people are aware and know zoonosis in Siddharthanagar municipality, Rupandehi. Age, gender, occupation, ethnicity, educational status of the respondents showed a significant difference concerning about zoonosis, which may have been because of the higher level of literacy among the specific risk factors. Thus, awareness is to be raised in the people regarding the threats and risks of zoonotic diseases to humans by the collaborative efforts of veterinarians, human health professionals as well as the government by conducting awareness campaigns, dramas or advertisements in the radio or television or by a distribution of pamphlets and printed materials among people.

References Références Referencias


This page is intentionally left blank
Efficacy of Intravenous Acetaminophen Compared to Oral Acetaminophen for the Management of Fever in Children

By Dr. Shailendra Kumar & Abhishek Pathak

Introduction: Human body temperature is controlled by the hypothalamus. Neurons in both the preoptic anterior hypothalamus and the posterior hypothalamus receive two kinds of signals: one from peripheral nerves that transmit information from warmth/cold receptors in the skin and the other from the temperature of the blood bathing the region. These two types of signals are integrated by the thermoregulatory center of the hypothalamus to maintain normal temperature. In a neutral temperature environment, the metabolic rate of humans produces more heat than is necessary to maintain the core body temperature in the range of 36.5–37.5°C (97.7–99.5°F). A normal body temperature is maintained ordinarily, despite environmental variations, because the hypothalamic thermoregulatory center balances the excess heat production derived from metabolic activity in muscle and the liver with heat dissipation from the skin and lungs.[1]

GJMR-F Classification: NLMC Code: WB 152

Strictly as per the compliance and regulations of:
I. INTRODUCTION

Human body temperature is controlled by the hypothalamus. Neurons in both the preoptic anterior hypothalamus and the posterior hypothalamus receive two kinds of signals: one from peripheral nerves that transmit information from warmth/cold receptors in the skin and the other from the temperature of the blood bathing the region. These two types of signals are integrated by the thermoregulatory center of the hypothalamus to maintain normal temperature. In a neutral temperature environment, the metabolic rate of humans produces more heat than is necessary to maintain the core body temperature in the range of 36.5–37.5°C (97.7–99.5°F). A normal body temperature is maintained ordinarily, despite environmental variations, because the hypothalamic thermoregulatory center balances the excess heat production derived from metabolic activity in muscle and the liver with heat dissipation from the skin and lungs.[1]

Fever (also known as pyrexia or a febrile response) is caused by increase in body temperature above the normal range due to an increase in the temperature regulatory set-point in hypothalamus. The increase in set-point triggers increased muscle tone and causes a feeling of cold resulting in greater heat production and efforts to conserve heat. This results in an increase in body temperature. When the set-point temperature returns to normal a person feels hot and may begin to sweat.

Fever is one of the commonest presenting symptoms in clinical medicine in all age group patients. It is defined as oral temperature of >37.2°C (>98.9°F) in the morning or >37.7°C (>99.9°F) in the evening.[1]

Fever can be caused by a numerous ailments ranging from potentially serious conditions to very benign illness. This includes both infectious as well as non infectious cause. Infectious illness includes different viral, bacterial and parasitic infections (eg: common cold, urinary tract infections, meningitis, malaria, appendicitis etc). Non-infectious causes include vasculitis, deep vein thrombosis, allergic manifestation, malignancies etc.

Fever may be useful as a defense mechanism as the body's immune response can be strengthened at higher temperatures; however, this issue is controversial.

Fever accounts for a substantial proportion of emergency consultations. It is one of the leading patient complaints aside from abdominal pain and chest pain in all emergency department visits. Treatment with antipyretics not only reduces fever but also improves the associated other symptoms (eg: arthralgia, myalgia, headache, nausea, vomiting). It also causes undue worry among the anxious parents of sick kids. Hence treatments of fever with proper antipyretic medications are extremely important. Antipyretic medications such as ibuprofen or paracetamol are effective at lowering the temperature, which may improve comfort.

Both pharmacologic and nonpharmacologic methods like tepid sponging have been used to reduce body temperature in febrile patients. Extensive studies have been done in children comparing the efficacy of various antipyretics including paracetamol, ibuprofen, nimesulide, ketoprofen, propacetamol, and dipyrone.

Acetaminophen is a synthetic, nonopioid, centrally acting analgesic and antipyretic agent. It has a well-established efficacy profile, a well-understood risk/benefit ratio, and a very low potential for harmful drug–drug interactions. In recommended doses, acetaminophen is considered safe for infants, children, and adults. Although the exact site and mechanism of action of acetaminophen are not clearly defined, its effectiveness as an antipyretic agent has been attributed to its effect on the hypothalamic heat-regulating center.

Worldwide, acetaminophen is currently the most widely used analgesic and antipyretic. Per Oral (PO) acetaminophen was initially approved by the U.S. Food and Drug Administration (FDA) in 1951 and was first marketed in the United States in 1953. Acetaminophen has been well known as an effective analgesic and antipyretic. Intravenous (IV) acetaminophen is approved for the short-term treatment of acute pain and fever in approximately 80 countries outside of the United States and was first approved in Europe in 2001.
Studies on the efficacy of antipyretic drugs are very scarce. Most of the available studies on acetaminophen were carried out in endotoxin-induced febrile models and in intensive care patients.[10, 11, 12] Few studies have been done on oral diclofenac using varying doses or comparing it with ibuprofen or acetylsalicylic acid. Intravenous ketorolac has also been studied as an antipyretic in adults.[16]

To the best of our knowledge, there is very few literature available for comparing the antipyretic efficacy of paracetamol (both oral and intravenous) in children. Therefore, we decided to compare the antipyretic efficacy of oral and intravenous paracetamol in febrile children.

II. AIM AND OBJECTIVES

a) Aim
To determine efficacy of Intravenous Acetaminophen Compared to Oral Acetaminophen for the management of Fever in children.

b) Formulation of hypothesis
The use of Intravenous Acetaminophen Compared to Oral Acetaminophen for the Management of Fever in children has:

A) Primary outcome
The primary efficacy outcome will be the weighted sum of temperature differences from baseline at time T₀ through T₃₀₀ minutes.

B) Secondary outcomes
To assess tolerability of oral preparation as compared to intravenous preparation e.g. new onset constipation, allergic reaction and dry mouth.

III. MATERIALS AND METHODS

a) Type of study
Prospective Observational study.

b) Study period
One and Half Years- from October 2013 to April 2015.

c) Study Place
Department of Pediatrics Army Hospital (Research & Referral), Delhi Cantt.

d) Sample size
Based on the statistical calculation a total number of 200 cases were included in the study population in Army Hospital (Research & Referral), Delhi Cantt, India, a tertiary care hospital over one and half years from October 2013 to April 2015.

e) Inclusion Criteria
All admitted or out-patient department cases with fever more than 103°F.

f) Exclusion Criteria
1) Treated with any other medication having antipyretic effects within 2 days of admission.
2) Known hypersensitivity to acetaminophen or other NSAIDs.
3) Impaired liver function, active hepatic disease, or evidence of clinically significant liver and renal disease.

gh) Methodology
1. All pediatric cases between 1-12 years age, admitted to the Pediatric ward of Army Hospital (R&R), and those presenting to the Pediatric OPD with fever more than 103°F requiring IV/Oral acetaminophen were considered eligible for the study.
2. Written Informed consent was taken from parents before enrollment in the study and administration of the medicine.
3. Following receipt of consent, children were randomly allocated (using computer generated randomization) in two groups – one group receiving oral PCM and the other one receiving IV PCM divided into two groups alternaone group receiving oral acetaminophen (15mg/kg/dose) or and the other group receiving IV acetaminophen (15mg/kg/dose) as antipyretic. Children were enrolled in each group consecutively.
4. Baseline vital parameters including mean arterial pressure using non-invasive blood pressure monitor by oscillometric technique were recorded.
5. Following administration of the drug the child was monitored for the primary efficacy outcome.
6. Axillary temp. was recorded with mercury thermometer for 5 min every ½ hrly, till 6 hrs.
7. Child was monitored for any evidence of intolerance.
8. All data including the primary and secondary outcomes was recorded as per the Performa.

h) Ethical Consideration
We have obtained the necessary approval to conduct the study from the Institutional Ethics Committee of Army Hospital (Research and Referral) Delhi Cantt., India. The participants were given a full explanation about the purpose of the study and assurance about the confidentiality of the information and that the participation was optional. Consent of the parents of children was taken prior to enrolment to the study.

i) Statistical Analysis
All the statistical analysis was performed using SPSS version 20. The clinical profile of patients was analyzed by chi-square test for qualitative variables and Student t test for quantitative variables. 5% probability level was considered as statistically significant i.e., p<0.05.
j) Statement of Limitation

Time to a temperature reduction analysis; time to the specific event (e.g., time to specific temperature or rescue) estimated based on the Kaplan-Meier method (censored at 360 minutes if a subject did not achieve the specified temperature reduction); global evaluation at $T_{360}$ minutes summarized for each group by frequency and percentage for each categorical response and analyzed using unstratified Cochran-Mantel-Haenzel mean score test using integer scores; and continuous variables such as change in temperature, maximum temperature reduction, and percentage of subjects with a temperature of $<38.5^\circ\text{C}$, analysis should have carried out for other efficacy endpoints.

Flow Diagram of Patient Enrolment and Assessment

```
Eligible
     | Excluded
     |
Enrolled
     | Temp. $\geq 1030^\circ\text{F}$

Children receiving IV Acetaminophen

Children receiving Oral Acetaminophen

Assessed For Primary and Secondary Outcomes

Data Analysis
```

IV. RESULTS

The present study, carried out over a period of one and half years—from October 2013 to April 2015, was aimed at “Efficacy of Intravenous Acetaminophen Compared to Oral Acetaminophen for the Management of Fever in children” at Department of Pediatrics, Army Hospital (Research and Referral) Delhi Cantt., India.

Table 1: Study group Distribution

<table>
<thead>
<tr>
<th>Groups</th>
<th>Frequency</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>50.0</td>
</tr>
<tr>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>50.0</td>
</tr>
</tbody>
</table>
Efficacy of Intravenous Acetaminophen Compared to Oral Acetaminophen for the Management of Fever in Children

Figure 1: Study group Distribution

Table 2: Gender Distribution

<table>
<thead>
<tr>
<th>Sex</th>
<th>Frequency</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>141</td>
<td>70.5</td>
</tr>
<tr>
<td>Female</td>
<td>59</td>
<td>29.5</td>
</tr>
</tbody>
</table>

Figure 2: Gender Distribution

Table 3: Gender wise distribution of study group

<table>
<thead>
<tr>
<th>Crosstab</th>
<th>Sex</th>
<th></th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
<td>Total</td>
</tr>
<tr>
<td>Intravenous Acetaminophen</td>
<td>70</td>
<td>30</td>
<td>100</td>
</tr>
<tr>
<td>% of Total</td>
<td>35.0%</td>
<td>15.0%</td>
<td>50.0%</td>
</tr>
<tr>
<td>Oral Acetaminophen</td>
<td>71</td>
<td>29</td>
<td>100</td>
</tr>
<tr>
<td>% of Total</td>
<td>35.5%</td>
<td>14.5%</td>
<td>50.0%</td>
</tr>
<tr>
<td>Total</td>
<td>141</td>
<td>59</td>
<td>200</td>
</tr>
<tr>
<td>% of Total</td>
<td>70.5%</td>
<td>29.5%</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

© 2019 Global Journals
Figure 3: Gender wise distribution of study group

Table 4: Temperature decreased wise distribution of study group

<table>
<thead>
<tr>
<th>Groups</th>
<th>Temp decreased</th>
<th>Total</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Intravenous Acetaminophen</td>
<td>12</td>
<td>88</td>
<td>100</td>
</tr>
<tr>
<td>Oral Acetaminophen</td>
<td>9</td>
<td>91</td>
<td>100</td>
</tr>
<tr>
<td>Total</td>
<td>21</td>
<td>179</td>
<td>200</td>
</tr>
</tbody>
</table>

**Efficacy of Intravenous Acetaminophen Compared to Oral Acetaminophen for the Management of Fever in Children**

Global Journal of Medical Research (F) Volume XIX Issue IV Version I (Year 2019)
Figure 4: Temperature decreased wise distribution of study group

Table 5: Base line Statistics of all cases

<table>
<thead>
<tr>
<th>Base line Statistics of all Cases</th>
<th>Age (in Yrs.)</th>
<th>Weight (in Kgs)</th>
<th>HR (per Min)</th>
<th>RR (per Min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>6.7742</td>
<td>23.2975</td>
<td>118.4400</td>
<td>23.9200</td>
</tr>
<tr>
<td>Std. Error of Mean</td>
<td>.19361</td>
<td>.45287</td>
<td>.65604</td>
<td>.19637</td>
</tr>
<tr>
<td>Median</td>
<td>6.2500</td>
<td>22.0000</td>
<td>122.0000</td>
<td>24.0000</td>
</tr>
<tr>
<td>Mode</td>
<td>5.00</td>
<td>20.00</td>
<td>124.00</td>
<td>24.00</td>
</tr>
<tr>
<td>Std. Deviation</td>
<td>2.73807</td>
<td>6.40452</td>
<td>9.27776</td>
<td>2.77708</td>
</tr>
<tr>
<td>Percentiles</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>5.0000</td>
<td>18.0000</td>
<td>112.0000</td>
<td>22.0000</td>
</tr>
<tr>
<td>50</td>
<td>6.2500</td>
<td>22.0000</td>
<td>122.0000</td>
<td>24.0000</td>
</tr>
<tr>
<td>75</td>
<td>9.0000</td>
<td>28.0000</td>
<td>126.0000</td>
<td>26.0000</td>
</tr>
</tbody>
</table>

Figure 5: Base line Statistics of all cases
**Table 6: Study group wise comparison of different parameters**

<table>
<thead>
<tr>
<th></th>
<th>Groups</th>
<th>N</th>
<th>Mean</th>
<th>Std. Deviation</th>
<th>Std. Error Mean</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (in yrs.)</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>6.8085</td>
<td>2.6599</td>
<td>.26599</td>
<td>.860</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>6.74</td>
<td>2.8270</td>
<td>.28271</td>
<td></td>
</tr>
<tr>
<td>Weight (in Kgs)</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>23.295</td>
<td>5.9895</td>
<td>.59895</td>
<td>.996</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>23.3</td>
<td>6.8246</td>
<td>.68246</td>
<td></td>
</tr>
<tr>
<td>HR (per min)</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>118.44</td>
<td>9.3012</td>
<td>.93012</td>
<td>.850</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>118.32</td>
<td>9.0194</td>
<td>.90195</td>
<td></td>
</tr>
<tr>
<td>RR (per min)</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>23.92</td>
<td>2.4141</td>
<td>.24141</td>
<td>.419</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>23.52</td>
<td>2.4746</td>
<td>.24746</td>
<td></td>
</tr>
</tbody>
</table>

**Figure 6: Study group wise comparison of different parameters**

**Table 7: Time post dose mean temperature variation in the study groups**

<table>
<thead>
<tr>
<th></th>
<th>Groups</th>
<th>N</th>
<th>Mean</th>
<th>Std. Deviation</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>103.76</td>
<td>0.698</td>
<td>0.011</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>103.99</td>
<td>0.569</td>
<td></td>
</tr>
<tr>
<td>T30</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>102.44</td>
<td>0.536</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>103.24</td>
<td>0.789</td>
<td></td>
</tr>
<tr>
<td>T60</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>101.16</td>
<td>0.735</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>102.57</td>
<td>0.915</td>
<td></td>
</tr>
<tr>
<td>T90</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>100.18</td>
<td>0.798</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>101.8</td>
<td>0.669</td>
<td></td>
</tr>
<tr>
<td>T120</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>99.25</td>
<td>0.636</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>101.11</td>
<td>0.889</td>
<td></td>
</tr>
<tr>
<td>T150</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>98.6</td>
<td>0.835</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>101.41</td>
<td>1.015</td>
<td></td>
</tr>
<tr>
<td>T180</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>98.6</td>
<td>0.575</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>99.8</td>
<td>0.446</td>
<td></td>
</tr>
<tr>
<td>T210</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>98.6</td>
<td>0.413</td>
<td>0.154</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>99.15</td>
<td>0.666</td>
<td></td>
</tr>
<tr>
<td>T240</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>98.6</td>
<td>0.612</td>
<td>0.875</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>98.6</td>
<td>0.792</td>
<td></td>
</tr>
<tr>
<td>T270</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>98.6</td>
<td>0.505</td>
<td>0.651</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>98.6</td>
<td>0.472</td>
<td></td>
</tr>
<tr>
<td>T300</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>98.6</td>
<td>0.433</td>
<td>0.843</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>98.6</td>
<td>0.651</td>
<td></td>
</tr>
<tr>
<td>T330</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>98.6</td>
<td>0.689</td>
<td>0.845</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>98.6</td>
<td>0.723</td>
<td></td>
</tr>
<tr>
<td>T360</td>
<td>Intravenous Acetaminophen</td>
<td>100</td>
<td>98.6</td>
<td>0.305</td>
<td>0.925</td>
</tr>
<tr>
<td></td>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>98.6</td>
<td>0.205</td>
<td></td>
</tr>
</tbody>
</table>
**Figure 7:** Time post dose mean temperature variation in the study groups

**Table 8:** Allergic reaction wise distribution of study group

<table>
<thead>
<tr>
<th>Groups</th>
<th>Allergic reaction</th>
<th>Total</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Intravenous Acetaminophen</td>
<td>Number</td>
<td>93</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>% of Total</td>
<td>46.5%</td>
<td>3.5%</td>
</tr>
<tr>
<td>Oral Acetaminophen</td>
<td>Number</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>% of Total</td>
<td>50.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Total</td>
<td>Number</td>
<td>193</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>% of Total</td>
<td>96.5%</td>
<td>3.5%</td>
</tr>
</tbody>
</table>

**Figure 8:** Allergic reaction wise distribution of study group
Table 9: Additional dose wise distribution of study group

<table>
<thead>
<tr>
<th>Groups</th>
<th>Additional dose</th>
<th>Total</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Intravenous Acetaminophen</td>
<td>90</td>
<td>6</td>
<td>100</td>
</tr>
<tr>
<td>% of Total</td>
<td>45.0%</td>
<td>3.0%</td>
<td>50.0%</td>
</tr>
<tr>
<td>Oral Acetaminophen</td>
<td>94</td>
<td>10</td>
<td>100</td>
</tr>
<tr>
<td>% of Total</td>
<td>47.0%</td>
<td>5.0%</td>
<td>50.0%</td>
</tr>
<tr>
<td>Total</td>
<td>184</td>
<td>16</td>
<td>200</td>
</tr>
<tr>
<td>% of Total</td>
<td>92.0%</td>
<td>8.0%</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

Figure 9: Additional dose wise distribution of study group

Table 10: New onset constipation wise distribution of study

<table>
<thead>
<tr>
<th>Groups</th>
<th>New onset constipation</th>
<th>Total</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Intravenous Acetaminophen</td>
<td>92</td>
<td>8</td>
<td>100</td>
</tr>
<tr>
<td>% of Total</td>
<td>46.0%</td>
<td>4.0%</td>
<td>50.0%</td>
</tr>
<tr>
<td>Oral Acetaminophen</td>
<td>100</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>% of Total</td>
<td>50.0%</td>
<td>0.0%</td>
<td>50.0%</td>
</tr>
<tr>
<td>Total</td>
<td>192</td>
<td>8</td>
<td>200</td>
</tr>
<tr>
<td>% of Total</td>
<td>96.0%</td>
<td>4.0%</td>
<td>100.0%</td>
</tr>
</tbody>
</table>
Figure 10: New onset constipation wise distribution of study group

Table 11: Dry mouth wise distribution of study group

<table>
<thead>
<tr>
<th>Groups</th>
<th>Dry mouth</th>
<th>Total</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Intravenous Acetaminophen</td>
<td>Number</td>
<td>92</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>% of Total</td>
<td>46.0%</td>
<td>4.0%</td>
</tr>
<tr>
<td>Oral Acetaminophen</td>
<td>Number</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>% of Total</td>
<td>50.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Total</td>
<td>Number</td>
<td>192</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>% of Total</td>
<td>96.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
V. SUMMARY AND CONCLUSION

Acetaminophen has been a cornerstone of the management of mild to moderate pain and the treatment of fever for more than 50 years. An intravenous (IV) preparation would allow for rapid, reliable drug delivery to patients in the immediate post-operative setting or in cases where enteral administration is not possible due to underlying disease. The purpose of this study was to assess the dynamics of the onset of antipyretic efficacy of intravenous (IV) acetaminophen versus oral (PO) acetaminophen in the management of fever in children.

This observational single-dose study was conducted at Department of Pediatrics, Army Hospital (Research and Referral), a multispecialty tertiary care center in New Delhi in fever patients to assess the antipyretic efficacy of IV acetaminophen 15mg/kg/dose versus PO acetaminophen 15mg/kg/dose over 6 hours. Subjects were randomly assigned to receive either IV acetaminophen (n = 100) or PO acetaminophen (n = 100). The salient observations of this study are as follows:

- A total of 200 participants were enrolled, allocated groups and received study medication: 100 in the IV group and 100 in the PO acetaminophen group.
- Demographics and baseline characteristics were similar between the two groups and were normally distributed.
- The mean (±SD) age was 6.7 (±2.75) years, the mean weight was 23.3 (± 6.41) kg.
- The majority of subjects were male (71%). The sex distribution was similar in both the groups 70% males and 30% females.
- Allergic reaction was found in 7 (3.5%) patients in IV acetaminophen group and was absent in PO acetaminophen group [table 8, figure 8]. This association is found to be statistically significant (P value 0.007).
- Onset of constipation and dry mouth was found in 8 patients (4%) in IV acetaminophen group and was absent in PO acetaminophen group [table 10 & 11, figure 10 & 11]. This association is found to be statistically significant (P value 0.004).
- Additional dose was required in 06 patients (3%) in Intravenous acetaminophen group and 10 patients...
(5%) in Oral Acetaminophen group respectively. However, this association is not statistically significant (P value 0.297).

- Temperature was decreased in all patients in both the Intravenous and Oral acetaminophen groups except some had required some extra additional dose.

- Statistically significant differences in the WSTD through 180 minutes (p < 0.004) were observed in favor of the IV acetaminophen group when compared to those receiving PO acetaminophen. After 4 hours, there was no difference in the WSTD between the treatment groups.

- Significant changes in temperature were observed in favor of IV acetaminophen over PO at each time point from T0 through T180.

From the results of the present study, it may be concluded that a single dose of intravenous acetaminophen is safe and effective in reducing fever. Intravenous acetaminophen may be useful where patients are unable to tolerate oral administration or when rapid reduction of temperature is desirable.
FELLOWS

FELLOW OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (FARSM)

Global Journals Incorporate (USA) is accredited by Open Association of Research Society (OARS), U.S.A and in turn, awards “FARSM” title to individuals. The ‘FARSM’ title is accorded to a selected professional after the approval of the Editor-in-Chief/Editorial Board Members/Dean.

The “FARSM” is a dignified title which is accorded to a person's name viz. Dr. John E. Hall Ph.D., FARSS or William Walldroff, M.S., FARSM.

FARSM accrediting is an honor. It authenticates your research activities. After recognition as FARSM, you can add ‘FARSM’ title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and repute to your name. You may use it on your professional Counseling Materials such as CV, Resume, and Visiting Card etc.

The following benefits can be availed by you only for next three years from the date of certification:

FARSM designated members are entitled to avail a 40% discount while publishing their research papers (of a single author) with Global Journals Incorporation (USA), if the same is accepted by Editorial Board/Peer Reviewers. If you are a main author or co-author in case of multiple authors, you will be entitled to avail discount of 10%.

Once FARSM title is accorded, the Fellow is authorized to organize a symposium/seminar/conference on behalf of Global Journal Incorporation (USA). The Fellow can also participate in conference/seminar/symposium organized by another institution as representative of Global Journal. In both the cases, it is mandatory for him to discuss with us and obtain our consent.

You may join as member of the Editorial Board of Global Journals Incorporation (USA) after successful completion of three years as Fellow and as Peer Reviewer. In addition, it is also desirable that you should organize seminar/symposium/conference at least once.

We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.

© Copyright by Global Journals | Guidelines Handbook
The FARSM can go through standards of OARS. You can also play vital role if you have any suggestions so that proper amendment can take place to improve the same for the benefit of entire research community.

As FARSM, you will be given a renowned, secure and free professional email address with 100 GB of space e.g. johnhall@globaljournals.org. This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.

The FARSM will be eligible for a free application of standardization of their researches. Standardization of research will be subject to acceptability within stipulated norms as the next step after publishing in a journal. We shall depute a team of specialized research professionals who will render their services for elevating your researches to next higher level, which is worldwide open standardization.

The FARSM member can apply for grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A. Once you are designated as FARSM, you may send us a scanned copy of all of you credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria. After certification of all your credentials by OARS, they will be published on your Fellow Profile link on website https://associationofresearch.org which will be helpful to upgrade the dignity.

The FARSM members can avail the benefits of free research podcasting in Global Research Radio with their research documents. After publishing the work, (including published elsewhere worldwide with proper authorization) you can upload your research paper with your recorded voice or you can utilize chargeable services of our professional RJs to record your paper in their voice on request.

The FARSM member also entitled to get the benefits of free research podcasting of their research documents through video clips. We can also streamline your conference videos and display your slides/ online slides and online research video clips at reasonable charges, on request.
The FARSM is eligible to earn from sales proceeds of his/her researches/reference/review Books or literature, while publishing with Global Journals. The FARSS can decide whether he/she would like to publish his/her research in a closed manner. In this case, whenever readers purchase that individual research paper for reading, maximum 60% of its profit earned as royalty by Global Journals, will be credited to his/her bank account. The entire entitled amount will be credited to his/her bank account exceeding limit of minimum fixed balance. There is no minimum time limit for collection. The FARSM member can decide its price and we can help in making the right decision.

The FARSM member is eligible to join as a paid peer reviewer at Global Journals Incorporation (USA) and can get remuneration of 15% of author fees, taken from the author of a respective paper. After reviewing 5 or more papers you can request to transfer the amount to your bank account.

MEMBER OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (MARM)

The 'MARSM' title is accorded to a selected professional after the approval of the Editor-in-Chief / Editorial Board Members/Dean.

The “MARSM” is a dignified ornament which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., MARSM or William Walldroff, M.S., MARSM.

MARSM accrediting is an honor. It authenticates your research activities. After becoming MARSM, you can add 'MARSM' title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and repute to your name. You may use it on your professional Counseling Materials such as CV, Resume, Visiting Card and Name Plate etc.

The following benefits can be availed by you only for next three years from the date of certification.

MARSM designated members are entitled to avail a 25% discount while publishing their research papers (of a single author) in Global Journals Inc., if the same is accepted by our Editorial Board and Peer Reviewers. If you are a main author or co-author of a group of authors, you will get discount of 10%.

As MARSM, you will be given a renowned, secure and free professional email address with 30 GB of space e.g. johnhall@globaljournals.org. This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.
We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.

The MARSM member can apply for approval, grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A.

Once you are designated as MARSM, you may send us a scanned copy of all of your credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria.

It is mandatory to read all terms and conditions carefully.
Auxiliary Memberships

Institutional Fellow of Open Association of Research Society (USA) - OARS (USA)

Global Journals Incorporation (USA) is accredited by Open Association of Research Society, U.S.A (OARS) and in turn, affiliates research institutions as “Institutional Fellow of Open Association of Research Society” (IFOARS).

The “FARSC” is a dignified title which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., FARSC or William Walldroff, M.S., FARSC.

The IFOARS institution is entitled to form a Board comprised of one Chairperson and three to five board members preferably from different streams. The Board will be recognized as “Institutional Board of Open Association of Research Society”-(IBOARS).

The Institute will be entitled to following benefits:

The IBOARS can initially review research papers of their institute and recommend them to publish with respective journal of Global Journals. It can also review the papers of other institutions after obtaining our consent. The second review will be done by peer reviewer of Global Journals Incorporation (USA).

The Board is at liberty to appoint a peer reviewer with the approval of chairperson after consulting us.

The author fees of such paper may be waived off up to 40%.

The Global Journals Incorporation (USA) at its discretion can also refer double blind peer reviewed paper at their end to the board for the verification and to get recommendation for final stage of acceptance of publication.

The IBOARS can organize symposium/seminar/conference in their country on behalf of Global Journals Incorporation (USA)-OARS (USA). The terms and conditions can be discussed separately.

The Board can also play vital role by exploring and giving valuable suggestions regarding the Standards of “Open Association of Research Society, U.S.A (OARS)” so that proper amendment can take place for the benefit of entire research community. We shall provide details of particular standard only on receipt of request from the Board.

The board members can also join us as Individual Fellow with 40% discount on total fees applicable to Individual Fellow. They will be entitled to avail all the benefits as declared. Please visit Individual Fellow-sub menu of GlobalJournals.org to have more relevant details.
We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.

After nomination of your institution as “Institutional Fellow” and constantly functioning successfully for one year, we can consider giving recognition to your institute to function as Regional/Zonal office on our behalf. The board can also take up the additional allied activities for betterment after our consultation.

The following entitlements are applicable to individual Fellows:

Open Association of Research Society, U.S.A (OARS) By-laws states that an individual Fellow may use the designations as applicable, or the corresponding initials. The Credentials of individual Fellow and Associate designations signify that the individual has gained knowledge of the fundamental concepts. One is magnanimous and proficient in an expertise course covering the professional code of conduct, and follows recognized standards of practice.

Open Association of Research Society (US)/ Global Journals Incorporation (USA), as described in Corporate Statements, are educational, research publishing and professional membership organizations. Achieving our individual Fellow or Associate status is based mainly on meeting stated educational research requirements.

Disbursement of 40% Royalty earned through Global Journals: Researcher = 50%, Peer Reviewer = 37.50%, Institution = 12.50%. E.g. Out of 40%, the 20% benefit should be passed on to researcher, 15% benefit towards remuneration should be given to a reviewer and remaining 5% is to be retained by the institution.

We shall provide print version of 12 issues of any three journals [as per your requirement] out of our 38 journals worth $2376 USD.

Other:

The individual Fellow and Associate designations accredited by Open Association of Research Society (US) credentials signify guarantees following achievements:

- The professional accredited with Fellow honor, is entitled to various benefits viz. name, fame, honor, regular flow of income, secured bright future, social status etc.
In addition to above, if one is single author, then entitled to 40% discount on publishing research paper and can get 10%discount if one is co-author or main author among group of authors.

The Fellow can organize symposium/seminar/conference on behalf of Global Journals Incorporation (USA) and he/she can also attend the same organized by other institutes on behalf of Global Journals.

The Fellow can become member of Editorial Board Member after completing 3yrs.

The Fellow can earn 60% of sales proceeds from the sale of reference/review books/literature/publishing of research paper.

Fellow can also join as paid peer reviewer and earn 15% remuneration of author charges and can also get an opportunity to join as member of the Editorial Board of Global Journals Incorporation (USA)

• This individual has learned the basic methods of applying those concepts and techniques to common challenging situations. This individual has further demonstrated an in–depth understanding of the application of suitable techniques to a particular area of research practice.

Note:

In future, if the board feels the necessity to change any board member, the same can be done with the consent of the chairperson along with anyone board member without our approval.

In case, the chairperson needs to be replaced then consent of 2/3rd board members are required and they are also required to jointly pass the resolution copy of which should be sent to us. In such case, it will be compulsory to obtain our approval before replacement.

In case of “Difference of Opinion [if any]” among the Board members, our decision will be final and binding to everyone.
**Preferred Author Guidelines**

We accept the manuscript submissions in any standard (generic) format.

We typeset manuscripts using advanced typesetting tools like Adobe In Design, CorelDraw, TeXnicCenter, and TeXStudio. We usually recommend authors submit their research using any standard format they are comfortable with, and let Global Journals do the rest.

Alternatively, you can download our basic template from https://globaljournals.org/Template

Authors should submit their complete paper/article, including text illustrations, graphics, conclusions, artwork, and tables. Authors who are not able to submit manuscript using the form above can email the manuscript department at submit@globaljournals.org or get in touch with chiefeditor@globaljournals.org if they wish to send the abstract before submission.

### Before and during Submission

Authors must ensure the information provided during the submission of a paper is authentic. Please go through the following checklist before submitting:

1. Authors must go through the complete author guideline and understand and agree to Global Journals' ethics and code of conduct, along with author responsibilities.
2. Authors must accept the privacy policy, terms, and conditions of Global Journals.
3. Ensure corresponding author’s email address and postal address are accurate and reachable.
4. Manuscript to be submitted must include keywords, an abstract, a paper title, co-author(s’) names and details (email address, name, phone number, and institution), figures and illustrations in vector format including appropriate captions, tables, including titles and footnotes, a conclusion, results, acknowledgments and references.
5. Authors should submit paper in a ZIP archive if any supplementary files are required along with the paper.
6. Proper permissions must be acquired for the use of any copyrighted material.
7. Manuscript submitted must not have been submitted or published elsewhere and all authors must be aware of the submission.

**Declaration of Conflicts of Interest**

It is required for authors to declare all financial, institutional, and personal relationships with other individuals and organizations that could influence (bias) their research.

**Policy on Plagiarism**

Plagiarism is not acceptable in Global Journals submissions at all.

Plagiarized content will not be considered for publication. We reserve the right to inform authors’ institutions about plagiarism detected either before or after publication. If plagiarism is identified, we will follow COPE guidelines:

Authors are solely responsible for all the plagiarism that is found. The author must not fabricate, falsify or plagiarize existing research data. The following, if copied, will be considered plagiarism:

- Words (language)
- Ideas
- Findings
- Writings
- Diagrams
- Graphs
- Illustrations
- Lectures

© Copyright by Global Journals | Guidelines Handbook
Authorship Policies

Global Journals follows the definition of authorship set up by the Open Association of Research Society, USA. According to its guidelines, authorship criteria must be based on:

1. Substantial contributions to the conception and acquisition of data, analysis, and interpretation of findings.
2. Drafting the paper and revising it critically regarding important academic content.
3. Final approval of the version of the paper to be published.

Changes in Authorship

The corresponding author should mention the name and complete details of all co-authors during submission and in manuscript. We support addition, rearrangement, manipulation, and deletions in authors list till the early view publication of the journal. We expect that corresponding author will notify all co-authors of submission. We follow COPE guidelines for changes in authorship.

Copyright

During submission of the manuscript, the author is confirming an exclusive license agreement with Global Journals which gives Global Journals the authority to reproduce, reuse, and republish authors' research. We also believe in flexible copyright terms where copyright may remain with authors/employers/institutions as well. Contact your editor after acceptance to choose your copyright policy. You may follow this form for copyright transfers.

Appealing Decisions

Unless specified in the notification, the Editorial Board’s decision on publication of the paper is final and cannot be appealed before making the major change in the manuscript.

Acknowledgments

Contributors to the research other than authors credited should be mentioned in Acknowledgments. The source of funding for the research can be included. Suppliers of resources may be mentioned along with their addresses.

Declaration of funding sources

Global Journals is in partnership with various universities, laboratories, and other institutions worldwide in the research domain. Authors are requested to disclose their source of funding during every stage of their research, such as making analysis, performing laboratory operations, computing data, and using institutional resources, from writing an article to its submission. This will also help authors to get reimbursements by requesting an open access publication letter from Global Journals and submitting to the respective funding source.

Preparing your Manuscript

Authors can submit papers and articles in an acceptable file format: MS Word (doc, docx), LaTeX (.tex, .zip or .rar including all of your files), Adobe PDF (.pdf), rich text format (.rtf), simple text document (.txt), Open Document Text (.odt), and Apple Pages (.pages). Our professional layout editors will format the entire paper according to our official guidelines. This is one of the highlights of publishing with Global Journals—authors should not be concerned about the formatting of their paper. Global Journals accepts articles and manuscripts in every major language, be it Spanish, Chinese, Japanese, Portuguese, Russian, French, German, Dutch, Italian, Greek, or any other national language, but the title, subtitle, and abstract should be in English. This will facilitate indexing and the pre-peer review process.

The following is the official style and template developed for publication of a research paper. Authors are not required to follow this style during the submission of the paper. It is just for reference purposes.
**Manuscript Style Instruction (Optional)**

- Microsoft Word Document Setting Instructions.
- Font type of all text should be Swis721 Lt BT.
- Page size: 8.27” x 11”, left margin: 0.65, right margin: 0.65, bottom margin: 0.75.
- Paper title should be in one column of font size 24.
- Author name in font size of 11 in one column.
- Abstract: font size 9 with the word “Abstract” in bold italics.
- Main text: font size 10 with two justified columns.
- Two columns with equal column width of 3.38 and spacing of 0.2.
- First character must be three lines drop-capped.
- The paragraph before spacing of 1 pt and after of 0 pt.
- Line spacing of 1 pt.
- Large images must be in one column.
- The names of first main headings (Heading 1) must be in Roman font, capital letters, and font size of 10.
- The names of second main headings (Heading 2) must not include numbers and must be in italics with a font size of 10.

**Structure and Format of Manuscript**

The recommended size of an original research paper is under 15,000 words and review papers under 7,000 words. Research articles should be less than 10,000 words. Research papers are usually longer than review papers. Review papers are reports of significant research (typically less than 7,000 words, including tables, figures, and references)

A research paper must include:

a) A title which should be relevant to the theme of the paper.
b) A summary, known as an abstract (less than 150 words), containing the major results and conclusions.
c) Up to 10 keywords that precisely identify the paper’s subject, purpose, and focus.
d) An introduction, giving fundamental background objectives.
e) Resources and techniques with sufficient complete experimental details (wherever possible by reference) to permit repetition, sources of information must be given, and numerical methods must be specified by reference.
f) Results which should be presented concisely by well-designed tables and figures.
g) Suitable statistical data should also be given.
h) All data must have been gathered with attention to numerical detail in the planning stage.

Design has been recognized to be essential to experiments for a considerable time, and the editor has decided that any paper that appears not to have adequate numerical treatments of the data will be returned unrefereed.

i) Discussion should cover implications and consequences and not just recapitulate the results; conclusions should also be summarized.

j) There should be brief acknowledgments.

k) There ought to be references in the conventional format. Global Journals recommends APA format.

Authors should carefully consider the preparation of papers to ensure that they communicate effectively. Papers are much more likely to be accepted if they are carefully designed and laid out, contain few or no errors, are summarizing, and follow instructions. They will also be published with much fewer delays than those that require much technical and editorial correction.

The Editorial Board reserves the right to make literary corrections and suggestions to improve brevity.
**Format Structure**

*It is necessary that authors take care in submitting a manuscript that is written in simple language and adheres to published guidelines.*

All manuscripts submitted to Global Journals should include:

**Title**

The title page must carry an informative title that reflects the content, a running title (less than 45 characters together with spaces), names of the authors and co-authors, and the place(s) where the work was carried out.

**Author details**

The full postal address of any related author(s) must be specified.

**Abstract**

The abstract is the foundation of the research paper. It should be clear and concise and must contain the objective of the paper and inferences drawn. It is advised to not include big mathematical equations or complicated jargon.

Many researchers searching for information online will use search engines such as Google, Yahoo or others. By optimizing your paper for search engines, you will amplify the chance of someone finding it. In turn, this will make it more likely to be viewed and cited in further works. Global Journals has compiled these guidelines to facilitate you to maximize the web-friendliness of the most public part of your paper.

**Keywords**

A major lynchpin of research work for the writing of research papers is the keyword search, which one will employ to find both library and internet resources. Up to eleven keywords or very brief phrases have to be given to help data retrieval, mining, and indexing.

One must be persistent and creative in using keywords. An effective keyword search requires a strategy: planning of a list of possible keywords and phrases to try.

Choice of the main keywords is the first tool of writing a research paper. Research paper writing is an art. Keyword search should be as strategic as possible.

One should start brainstorming lists of potential keywords before even beginning searching. Think about the most important concepts related to research work. Ask, “What words would a source have to include to be truly valuable in a research paper?” Then consider synonyms for the important words.

It may take the discovery of only one important paper to steer in the right keyword direction because, in most databases, the keywords under which a research paper is abstracted are listed with the paper.

**Numerical Methods**

Numerical methods used should be transparent and, where appropriate, supported by references.

**Abbreviations**

Authors must list all the abbreviations used in the paper at the end of the paper or in a separate table before using them.

**Formulas and equations**

Authors are advised to submit any mathematical equation using either MathJax, KaTeX, or LaTeX, or in a very high-quality image.

**Tables, Figures, and Figure Legends**

Tables: Tables should be cautiously designed, uncrowned, and include only essential data. Each must have an Arabic number, e.g., Table 4, a self-explanatory caption, and be on a separate sheet. Authors must submit tables in an editable format and not as images. References to these tables (if any) must be mentioned accurately.
Figures are supposed to be submitted as separate files. Always include a citation in the text for each figure using Arabic numbers, e.g., Fig. 4. Artwork must be submitted online in vector electronic form or by emailing it.

**Preparation of Electronic Figures for Publication**

Although low-quality images are sufficient for review purposes, print publication requires high-quality images to prevent the final product being blurred or fuzzy. Submit (possibly by e-mail) EPS (line art) or TIFF (halftone/photographs) files only. MS PowerPoint and Word Graphics are unsuitable for printed pictures. Avoid using pixel-oriented software. Scans (TIFF only) should have a resolution of at least 350 dpi (halftone) or 700 to 1100 dpi (line drawings). Please give the data for figures in black and white or submit a Color Work Agreement form. EPS files must be saved with fonts embedded (and with a TIFF preview, if possible).

For scanned images, the scanning resolution at final image size ought to be as follows to ensure good reproduction: line art: >650 dpi; halftones (including gel photographs): >350 dpi; figures containing both halftone and line images: >650 dpi.

Color charges: Authors are advised to pay the full cost for the reproduction of their color artwork. Hence, please note that if there is color artwork in your manuscript when it is accepted for publication, we would require you to complete and return a Color Work Agreement form before your paper can be published. Also, you can email your editor to remove the color fee after acceptance of the paper.

**Tips for writing a good quality Medical Research Paper**

1. **Choosing the topic:** In most cases, the topic is selected by the interests of the author, but it can also be suggested by the guides. You can have several topics, and then judge which you are most comfortable with. This may be done by asking several questions of yourself, like "Will I be able to carry out a search in this area? Will I find all necessary resources to accomplish the search? Will I be able to find all information in this field area?" If the answer to this type of question is "yes," then you ought to choose that topic. In most cases, you may have to conduct surveys and visit several places. Also, you might have to do a lot of work to find all the rises and falls of the various data on that subject. Sometimes, detailed information plays a vital role, instead of short information. Evaluators are human: The first thing to remember is that evaluators are also human beings. They are not only meant for rejecting a paper. They are here to evaluate your paper. So present your best aspect.

2. **Think like evaluators:** If you are in confusion or getting demotivated because your paper may not be accepted by the evaluators, then think, and try to evaluate your paper like an evaluator. Try to understand what an evaluator wants in your research paper, and you will automatically have your answer. Make blueprints of paper: The outline is the plan or framework that will help you to arrange your thoughts. It will make your paper logical. But remember that all points of your outline must be related to the topic you have chosen.

3. **Ask your guides:** If you are having any difficulty with your research, then do not hesitate to share your difficulty with your guide (if you have one). They will surely help you out and resolve your doubts. If you can't clarify what exactly you require for your work, then ask your supervisor to help you with an alternative. He or she might also provide you with a list of essential readings.

4. **Use of computer is recommended:** As you are doing research in the field of medical research then this point is quite obvious. Use right software: Always use good quality software packages. If you are not capable of judging good software, then you can lose the quality of your paper unknowingly. There are various programs available to help you which you can get through the internet.

5. **Use the internet for help:** An excellent start for your paper is using Google. It is a wondrous search engine, where you can have your doubts resolved. You may also read some answers for the frequent question of how to write your research paper or find a model research paper. You can download books from the internet. If you have all the required books, place importance on reading, selecting, and analyzing the specified information. Then sketch out your research paper. Use big pictures: You may use encyclopedias like Wikipedia to get pictures with the best resolution. At Global Journals, you should strictly follow here.
6. **Bookmarks are useful**: When you read any book or magazine, you generally use bookmarks, right? It is a good habit which helps to not lose your continuity. You should always use bookmarks while searching on the internet also, which will make your search easier.

7. **Revise what you wrote**: When you write anything, always read it, summarize it, and then finalize it.

8. **Make every effort**: Make every effort to mention what you are going to write in your paper. That means always have a good start. Try to mention everything in the introduction—what is the need for a particular research paper. Polish your work with good writing skills and always give an evaluator what he wants. Make backups: When you are going to do any important thing like making a research paper, you should always have backup copies of it either on your computer or on paper. This protects you from losing any portion of your important data.

9. **Produce good diagrams of your own**: Always try to include good charts or diagrams in your paper to improve quality. Using several unnecessary diagrams will degrade the quality of your paper by creating a hodgepodge. So always try to include diagrams which were made by you to improve the readability of your paper. Use of direct quotes: When you do research relevant to literature, history, or current affairs, then use of quotes becomes essential, but if the study is relevant to science, use of quotes is not preferable.

10. **Use proper verb tense**: Use proper verb tenses in your paper. Use past tense to present those events that have happened. Use present tense to indicate events that are going on. Use future tense to indicate events that will happen in the future. Use of wrong tenses will confuse the evaluator. Avoid sentences that are incomplete.

11. **Pick a good study spot**: Always try to pick a spot for your research which is quiet. Not every spot is good for studying.

12. **Know what you know**: Always try to know what you know by making objectives, otherwise you will be confused and unable to achieve your target.

13. **Use good grammar**: Always use good grammar and words that will have a positive impact on the evaluator; use of good vocabulary does not mean using tough words which the evaluator has to find in a dictionary. Do not fragment sentences. Eliminate one-word sentences. Do not ever use a big word when a smaller one would suffice. Verbs have to be in agreement with their subjects. In a research paper, do not start sentences with conjunctions or finish them with prepositions. When writing formally, it is advisable to never split an infinitive because someone will (wrongly) complain. Avoid clichés like a disease. Always shun irritating alliteration. Use language which is simple and straightforward. Put together a neat summary.

14. **Arrangement of information**: Each section of the main body should start with an opening sentence, and there should be a changeover at the end of the section. Give only valid and powerful arguments for your topic. You may also maintain your arguments with records.

15. **Never start at the last minute**: Always allow enough time for research work. Leaving everything to the last minute will degrade your paper and spoil your work.

16. **Multitasking in research is not good**: Doing several things at the same time is a bad habit in the case of research activity. Research is an area where everything has a particular time slot. Divide your research work into parts, and do a particular part in a particular time slot.

17. **Never copy others' work**: Never copy others' work and give it your name because if the evaluator has seen it anywhere, you will be in trouble. Take proper rest and food: No matter how many hours you spend on your research activity, if you are not taking care of your health, then all your efforts will have been in vain. For quality research, take proper rest and food.

18. **Go to seminars**: Attend seminars if the topic is relevant to your research area. Utilize all your resources.

19. **Refresh your mind after intervals**: Try to give your mind a rest by listening to soft music or sleeping in intervals. This will also improve your memory. Acquire colleagues: Always try to acquire colleagues. No matter how sharp you are, if you acquire colleagues, they can give you ideas which will be helpful to your research.
20. **Think technically:** Always think technically. If anything happens, search for its reasons, benefits, and demerits. Think and then print: When you go to print your paper, check that tables are not split, headings are not detached from their descriptions, and page sequence is maintained.

21. **Adding unnecessary information:** Do not add unnecessary information like "I have used MS Excel to draw graphs." Irrelevant and inappropriate material is superfluous. Foreign terminology and phrases are not apropos. One should never take a broad view. Analogy is like feathers on a snake. Use words properly, regardless of how others use them. Remove quotations. Puns are for kids, not grunt readers. Never oversimplify: When adding material to your research paper, never go for oversimplification; this will definitely irritate the evaluator. Be specific. Never use rhythmic redundancies. Contractions shouldn't be used in a research paper. Comparisons are as terrible as clichés. Give up ampersands, abbreviations, and so on. Remove commas that are not necessary. Parenthetical words should be between brackets or commas. Understatement is always the best way to put forward earth-shaking thoughts. Give a detailed literary review.

22. **Report concluded results:** Use concluded results. From raw data, filter the results, and then conclude your studies based on measurements and observations taken. An appropriate number of decimal places should be used. Parenthetical remarks are prohibited here. Proofread carefully at the final stage. At the end, give an outline to your arguments. Spot perspectives of further study of the subject. Justify your conclusion at the bottom sufficiently, which will probably include examples.

23. **Upon conclusion:** Once you have concluded your research, the next most important step is to present your findings. Presentation is extremely important as it is the definite medium though which your research is going to be in print for the rest of the crowd. Care should be taken to categorize your thoughts well and present them in a logical and neat manner. A good quality research paper format is essential because it serves to highlight your research paper and bring to light all necessary aspects of your research.

**Informal Guidelines of Research Paper Writing**

**Key points to remember:**

- Submit all work in its final form.
- Write your paper in the form which is presented in the guidelines using the template.
- Please note the criteria peer reviewers will use for grading the final paper.

**Final points:**

One purpose of organizing a research paper is to let people interpret your efforts selectively. The journal requires the following sections, submitted in the order listed, with each section starting on a new page:

*The introduction:* This will be compiled from reference matter and reflect the design processes or outline of basis that directed you to make a study. As you carry out the process of study, the method and process section will be constructed like that. The results segment will show related statistics in nearly sequential order and direct reviewers to similar intellectual paths throughout the data that you gathered to carry out your study.

*The discussion section:* This will provide understanding of the data and projections as to the implications of the results. The use of good quality references throughout the paper will give the effort trustworthiness by representing an alertness to prior workings.

Writing a research paper is not an easy job, no matter how trouble-free the actual research or concept. Practice, excellent preparation, and controlled record-keeping are the only means to make straightforward progression.

**General style:** Specific editorial column necessities for compliance of a manuscript will always take over from directions in these general guidelines.

**To make a paper clear:** Adhere to recommended page limits.
Mistakes to avoid:

- Insertion of a title at the foot of a page with subsequent text on the next page.
- Separating a table, chart, or figure—confine each to a single page.
- Submitting a manuscript with pages out of sequence.
- In every section of your document, use standard writing style, including articles ("a" and "the").
- Keep paying attention to the topic of the paper.
- Use paragraphs to split each significant point (excluding the abstract).
- Align the primary line of each section.
- Present your points in sound order.
- Use present tense to report well-accepted matters.
- Use past tense to describe specific results.
- Do not use familiar wording; don't address the reviewer directly. Don't use slang or superlatives.
- Avoid use of extra pictures—include only those figures essential to presenting results.

Title page:

Choose a revealing title. It should be short and include the name(s) and address(es) of all authors. It should not have acronyms or abbreviations or exceed two printed lines.

Abstract: This summary should be two hundred words or less. It should clearly and briefly explain the key findings reported in the manuscript and must have precise statistics. It should not have acronyms or abbreviations. It should be logical in itself. Do not cite references at this point.

An abstract is a brief, distinct paragraph summary of finished work or work in development. In a minute or less, a reviewer can be taught the foundation behind the study, common approaches to the problem, relevant results, and significant conclusions or new questions.

Write your summary when your paper is completed because how can you write the summary of anything which is not yet written? Wealth of terminology is very essential in abstract. Use comprehensive sentences, and do not sacrifice readability for brevity; you can maintain it succinctly by phrasing sentences so that they provide more than a lone rationale. The author can at this moment go straight to shortening the outcome. Sum up the study with the subsequent elements in any summary. Try to limit the initial two items to no more than one line each.

Reason for writing the article—theory, overall issue, purpose.

- Fundamental goal.
- To-the-point depiction of the research.
- Consequences, including definite statistics—if the consequences are quantitative in nature, account for this; results of any numerical analysis should be reported. Significant conclusions or questions that emerge from the research.

Approach:

- Single section and succinct.
- An outline of the job done is always written in past tense.
- Concentrate on shortening results—limit background information to a verdict or two.
- Exact spelling, clarity of sentences and phrases, and appropriate reporting of quantities (proper units, important statistics) are just as significant in an abstract as they are anywhere else.

Introduction:

The introduction should "introduce" the manuscript. The reviewer should be presented with sufficient background information to be capable of comprehending and calculating the purpose of your study without having to refer to other works. The basis for the study should be offered. Give the most important references, but avoid making a comprehensive appraisal of the topic. Describe the problem visibly. If the problem is not acknowledged in a logical, reasonable way, the reviewer will give no attention to your results. Speak in common terms about techniques used to explain the problem, if needed, but do not present any particulars about the protocols here.
The following approach can create a valuable beginning:

- Explain the value (significance) of the study.
- Defend the model—why did you employ this particular system or method? What is its compensation? Remark upon its appropriateness from an abstract point of view as well as pointing out sensible reasons for using it.
- Present a justification. State your particular theory(-ies) or aim(s), and describe the logic that led you to choose them.
- Briefly explain the study’s tentative purpose and how it meets the declared objectives.

Approach:

Use past tense except for when referring to recognized facts. After all, the manuscript will be submitted after the entire job is done. Sort out your thoughts; manufacture one key point for every section. If you make the four points listed above, you will need at least four paragraphs. Present surrounding information only when it is necessary to support a situation. The reviewer does not desire to read everything you know about a topic. Shape the theory specifically—do not take a broad view.

As always, give awareness to spelling, simplicity, and correctness of sentences and phrases.

Procedures (methods and materials):

This part is supposed to be the easiest to carve if you have good skills. A soundly written procedures segment allows a capable scientist to replicate your results. Present precise information about your supplies. The suppliers and clarity of reagents can be helpful bits of information. Present methods in sequential order, but linked methodologies can be grouped as a segment. Be concise when relating the protocols. Attempt to give the least amount of information that would permit another capable scientist to replicate your outcome, but be cautious that vital information is integrated. The use of subheadings is suggested and ought to be synchronized with the results section.

When a technique is used that has been well-described in another section, mention the specific item describing the way, but draw the basic principle while stating the situation. The purpose is to show all particular resources and broad procedures so that another person may use some or all of the methods in one more study or referee the scientific value of your work. It is not to be a step-by-step report of the whole thing you did, nor is a methods section a set of orders.

Materials:

Materials may be reported in part of a section or else they may be recognized along with your measures.

Methods:

- Report the method and not the particulars of each process that engaged the same methodology.
- Describe the method entirely.
- To be succinct, present methods under headings dedicated to specific dealings or groups of measures.
- Simplify—detail how procedures were completed, not how they were performed on a particular day.
- If well-known procedures were used, account for the procedure by name, possibly with a reference, and that’s all.

Approach:

It is embarrassing to use vigorous voice when documenting methods without using first person, which would focus the reviewer’s interest on the researcher rather than the job. As a result, when writing up the methods, most authors use third person passive voice.

Use standard style in this and every other part of the paper—avoid familiar lists, and use full sentences.

What to keep away from:

- Resources and methods are not a set of information.
- Skip all descriptive information and surroundings—save it for the argument.
- Leave out information that is immaterial to a third party.
Results:
The principle of a results segment is to present and demonstrate your conclusion. Create this part as entirely objective details of the outcome, and save all understanding for the discussion.

The page length of this segment is set by the sum and types of data to be reported. Use statistics and tables, if suitable, to present consequences most efficiently.

You must clearly differentiate material which would usually be incorporated in a study editorial from any unprocessed data or additional appendix matter that would not be available. In fact, such matters should not be submitted at all except if requested by the instructor.

Content:
- Sum up your conclusions in text and demonstrate them, if suitable, with figures and tables.
- In the manuscript, explain each of your consequences, and point the reader to remarks that are most appropriate.
- Present a background, such as by describing the question that was addressed by creation of an exacting study.
- Explain results of control experiments and give remarks that are not accessible in a prescribed figure or table, if appropriate.
- Examine your data, then prepare the analyzed (transformed) data in the form of a figure (graph), table, or manuscript.

What to stay away from:
- Do not discuss or infer your outcome, report surrounding information, or try to explain anything.
- Do not include raw data or intermediate calculations in a research manuscript.
- Do not present similar data more than once.
- A manuscript should complement any figures or tables, not duplicate information.
- Never confuse figures with tables—there is a difference.

Approach:
As always, use past tense when you submit your results, and put the whole thing in a reasonable order.

Put figures and tables, appropriately numbered, in order at the end of the report.

If you desire, you may place your figures and tables properly within the text of your results section.

Figures and tables:
If you put figures and tables at the end of some details, make certain that they are visibly distinguished from any attached appendix materials, such as raw facts. Whatever the position, each table must be titled, numbered one after the other, and include a heading. All figures and tables must be divided from the text.

Discussion:
The discussion is expected to be the trickiest segment to write. A lot of papers submitted to the journal are discarded based on problems with the discussion. There is no rule for how long an argument should be.

Position your understanding of the outcome visibly to lead the reviewer through your conclusions, and then finish the paper with a summing up of the implications of the study. The purpose here is to offer an understanding of your results and support all of your conclusions, using facts from your research and generally accepted information, if suitable. The implication of results should be fully described.

Infer your data in the conversation in suitable depth. This means that when you clarify an observable fact, you must explain mechanisms that may account for the observation. If your results vary from your prospect, make clear why that may have happened. If your results agree, then explain the theory that the proof supported. It is never suitable to just state that the data approved the prospect, and let it drop at that. Make a decision as to whether each premise is supported or discarded or if you cannot make a conclusion with assurance. Do not just dismiss a study or part of a study as "uncertain."
Research papers are not acknowledged if the work is imperfect. Draw what conclusions you can based upon the results that you have, and take care of the study as a finished work.

- You may propose future guidelines, such as how an experiment might be personalized to accomplish a new idea.
- Give details of all of your remarks as much as possible, focusing on mechanisms.
- Make a decision as to whether the tentative design sufficiently addressed the theory and whether or not it was correctly restricted. Try to present substitute explanations if they are sensible alternatives.
- One piece of research will not counter an overall question, so maintain the large picture in mind. Where do you go next? The best studies unlock new avenues of study. What questions remain?
- Recommendations for detailed papers will offer supplementary suggestions.

**Approach:**

When you refer to information, differentiate data generated by your own studies from other available information. Present work done by specific persons (including you) in past tense.

Describe generally acknowledged facts and main beliefs in present tense.

**The Administration Rules**

Administration Rules to Be Strictly Followed before Submitting Your Research Paper to Global Journals Inc.

*Please read the following rules and regulations carefully before submitting your research paper to Global Journals Inc. to avoid rejection.*

**Segment draft and final research paper:** You have to strictly follow the template of a research paper, failing which your paper may get rejected. You are expected to write each part of the paper wholly on your own. The peer reviewers need to identify your own perspective of the concepts in your own terms. Please do not extract straight from any other source, and do not rephrase someone else's analysis. Do not allow anyone else to proofread your manuscript.

**Written material:** You may discuss this with your guides and key sources. Do not copy anyone else's paper, even if this is only imitation, otherwise it will be rejected on the grounds of plagiarism, which is illegal. Various methods to avoid plagiarism are strictly applied by us to every paper, and, if found guilty, you may be blacklisted, which could affect your career adversely. To guard yourself and others from possible illegal use, please do not permit anyone to use or even read your paper and file.
Please note that following table is only a Grading of "Paper Compilation" and not on "Performed/Stated Research" whose grading solely depends on Individual Assigned Peer Reviewer and Editorial Board Member. These can be available only on request and after decision of Paper. This report will be the property of Global Journals.

<table>
<thead>
<tr>
<th>Topics</th>
<th>Grades</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A-B</td>
</tr>
<tr>
<td>Abstract</td>
<td>Clear and concise with appropriate content, Correct format. 200 words or below</td>
</tr>
<tr>
<td>Introduction</td>
<td>Containing all background details with clear goal and appropriate details, flow specification, no grammar and spelling mistake, well organized sentence and paragraph, reference cited</td>
</tr>
<tr>
<td>Methods and Procedures</td>
<td>Clear and to the point with well arranged paragraph, precision and accuracy of facts and figures, well organized subheads</td>
</tr>
<tr>
<td>Result</td>
<td>Well organized, Clear and specific, Correct units with precision, correct data, well structuring of paragraph, no grammar and spelling mistake</td>
</tr>
<tr>
<td>Discussion</td>
<td>Well organized, meaningful specification, sound conclusion, logical and concise explanation, highly structured paragraph reference cited</td>
</tr>
<tr>
<td>References</td>
<td>Complete and correct format, well organized</td>
</tr>
</tbody>
</table>